Cerebral amyloid angiopathy (CAA) …

Stroke & Vascular Disorders

Updated 07.05.2023
Released 05.16.1997
Expires For CME 07.05.2026

Cerebral amyloid angiopathy

Authors: Anand Viswanathan MD PhD, Maria Clara Zanon Zotin MD, Mariel Kozberg MD PhD

See Contributor Disclosures

Editor: Steven R Levine MD

Cerebral amyloid angiopathy

In This Article

Quick Link

Introduction

Overview

Cerebral amyloid angiopathy is recognized as a major cause of intracerebral hemorrhage in the elderly, as well as an important contributor to vascular cognitive impairment and dementia. The following are advances highlighted in the article: (1) the updated Boston criteria version 2.0 for the diagnosis of cerebral amyloid angiopathy, (2) the pathophysiological framework of cerebral amyloid angiopathy progression, and (3) the potential transmissibility of cerebral amyloid angiopathy through cadaveric dura matter exposure.

Key points

	• Cerebral amyloid angiopathy is a common neuropathology in the aging brain, most often recognized in clinical practice as the cause of multiple, strictly lobar intracerebral hemorrhages, microbleeds, or superficial sulcal/meningeal bleeding.
	• Cerebral amyloid angiopathy-related microbleeds and superficial sulcal/meningeal bleeding are sensitively detected by T2*-weighted gradient-echo or susceptibility-weighted imaging MRI techniques.
	• Advanced cerebral amyloid angiopathy is also associated with nonhemorrhagic brain lesions, such as white matter T2-hyperintensities, especially with a multifocal subcortical pattern, enlarged perivascular spaces in the centrum semiovale, and cortical microinfarcts.
	• The presence of cortical superficial siderosis is the strongest risk factor for subsequent lobar intracerebral hemorrhage in patients with cerebral amyloid angiopathy.
	• Reasonable steps for limiting the risk of recurrent cerebral amyloid angiopathy–related hemorrhage are blood pressure control, avoidance of anticoagulation in patients with biomarkers proven to convey high risk, and withholding of other antithrombotics in the absence of clear-cut indication.
	• A subset of cerebral amyloid angiopathy presents with subacute mental status changes, headache, seizures, and amyloid-related vascular inflammation, related in at least some instances to anti-amyloid autoantibodies in the cerebrospinal fluid and often improving with immunosuppressive treatment.

Historical note and terminology

Cerebral amyloid angiopathy has been recognized since the early part of the 20th century. In the German literature in 1907 and 1909, Fischer and Oppenheim described cases that, in retrospect, probably were cerebral amyloid angiopathy (64). Early labels for this clinicopathologic condition included “drusige Entartung der Artien und Kapillaren” and “amyloidose cerebrale et meningee.” In 1927, Divry described amyloid in vessel walls and neuritic plaques, based on birefringence when viewed under polarized light with Congo red staining, leading to the term “congophilic angiopathy.” In 1952, Morel and Wildi coined the term “dyshoric angiopathy” to describe vascular amyloid that invades the surrounding parenchyma. In 1935, the occurrence of a familial form of cerebral amyloid angiopathy in Iceland was described by Arnason and later labeled “hereditary cerebral hemorrhage with amyloid—Icelandic type” (04). A second familial form was recognized in the Netherlands in 1964 by Luyendijk and later labeled “hereditary cerebral hemorrhage with amyloid—Dutch type.” Although an association of cerebral amyloid angiopathy with Alzheimer disease was recognized in the 1940s, it was not until the 1970s that Jellinger and others realized that cerebral amyloid angiopathy is an integral part of Alzheimer disease (95). Also in the 1970s, several groups suggested a relation between cerebral amyloid angiopathy and nontraumatic intracerebral hemorrhage. Perhaps the most pivotal event in the history of cerebral amyloid occurred in 1984 when Glenner and Wong isolated and partially sequenced the amyloid protein found in meningeal arteries of brains of patients with Alzheimer disease and Down syndrome (67). In 1987, Pardridge and colleagues isolated and partially sequenced the same amyloid peptide from intraparenchymal arterioles in patients with Alzheimer disease (143). Currently, more than 10 central nervous system diseases have been associated with various forms of cerebral amyloid angiopathy. Over the last decades, interest in cerebral amyloid angiopathy has escalated, spurred by the development of molecular biological techniques and neuroimaging methods to dissect the cerebral amyloidoses, including cerebral amyloid angiopathy–related hemorrhage and Alzheimer disease.

Clinical manifestations

Presentation and course

	• Cerebral amyloid angiopathy is a common neuropathology in the aging brain that is most often recognized in clinical practice as the cause of multiple, strictly lobar intracerebral hemorrhages, microbleeds, or superficial sulcal and meningeal bleeding.
	• Patients with cerebral amyloid angiopathy can present with stroke or stroke-like symptoms (symptomatic intracerebral hemorrhage or transient focal neurologic episodes (TFNEs), previously referred to as “amyloid spells”), or cognitive impairment or dementia.
	• Cerebral amyloid angiopathy-related microbleeds and superficial sulcal and meningeal bleeding are sensitively detected by T2*-weighted gradient-echo or susceptibility-weighted imaging MRI techniques.

It is important to distinguish the following disorders related to deposition of amyloid beta in the central nervous system from the systemic amyloidoses in which amyloid is deposited in the peripheral nervous system and other organs. Although the familial oculoleptomeningeal amyloidoses can affect sites both in and outside the central nervous system, brain and vascular involvement are typically not prominent features of these disorders.

Spontaneous intracerebral hemorrhage. Cerebral amyloid angiopathy most commonly appears in a sporadic form associated with aging. A classic vascular presentation of sporadic cerebral amyloid angiopathy is lobar hemorrhage, often recurrent or multifocal, in an elderly individual.

Cerebral amyloid angiopathy with lobar hemorrhage (CT)

CT showing lobar hemorrhage secondary to cerebral amyloid angiopathy (Contributed by Dr. Jeffrey L Saver.)

Cerebral amyloid angiopathy has been identified as responsible for 10% to 20% of primary intracerebral hemorrhages in autopsy series and 34% of primary intracerebral hemorrhages in a clinical series drawn from various populations (92; 96; 75). The associated hemorrhages often rupture into the subarachnoid space; these features contrast with hypertensive hemorrhages, which preferentially rupture into the ventricular space. In several series, 9% to 53% of clinically significant hemorrhages related to cerebral amyloid angiopathy were multiple.

Cerebral amyloid angiopathy-associated lobar hemorrhage in an elderly patient with Alzheimer disease

Right frontal lobe shows swelling and a large amount of acute hemorrhage extending into the subarachnoid space. Underlying brain parenchyma showed a large right frontal intracerebral hemorrhage associated with cerebral amyloid ang...

Controlling for lobar volume, cerebral amyloid angiopathy-related hemorrhage tends to occur most commonly per cc of tissue in the occipital cortex, though all lobes can be affected (195; 165). Cerebellar and basal ganglia intracerebral hemorrhages secondary to cerebral amyloid angiopathy occur infrequently, and brainstem hemorrhage is extremely rare. Subclinical superficial sulcal/meningeal bleeding is common, appearing in 23 of 28 (61%) pathologically proven cases of cerebral amyloid angiopathy (113), and it may be associated with increased risk of recurrent intracerebral hemorrhage (50; 2017a 162; 152; 112) and further sulcal bleeding events (151; 150). It has been shown that sulcal bleeding events can be the first presentation for patients with cerebral amyloid angiopathy (38). Cortical superficial siderosis, which results from these sulcal and meningeal bleeding events, is relatively rare in healthy individuals in the population (149; 203). In patients with cerebral amyloid angiopathy, superficial siderosis progression can be easily recognized and semiquantitatively measured using serial MRIs. In patients with symptomatic cerebral amyloid angiopathy presenting without lobar intracerebral hemorrhage, superficial siderosis evolution assessed on MRI follow-up independently predicts increased symptomatic intracerebral hemorrhage risk (HR: 3.76; 95%CI: 1.37-10.35; P=0.010) at roughly 1 year (42). The locations of cerebral amyloid angiopathy-related brain hemorrhages reflect the distribution of the cerebral amyloid angiopathy pathology, a microangiopathy that most frequently affects neocortex and the overlying leptomeninges, rarely the cerebellum (including meninges), and almost never the deep hemispheric or brainstem structures (140). This pattern of localization helps distinguish cerebral amyloid angiopathy-related intracerebral hemorrhage from the more characteristically deep hemispheric bleeds associated with hypertension. It has been recognized that a combination of both hypertensive and vascular amyloid pathologies is not uncommon in patients with intracerebral hemorrhage (144). The distribution of cerebellar hemorrhagic features may also help distinguish the underlying microangiopathy at play. In patients with spontaneous intracerebral hemorrhage, strictly superficial cerebellar microbleeds have been associated with clinically diagnosed and pathologically proven cerebral amyloid angiopathy (145). Additionally, cerebellar superficial siderosis has recently been associated with cerebral amyloid angiopathy (104).

The clinical features of intracerebral hemorrhage secondary to cerebral amyloid angiopathy include an abrupt onset of headache, focal lobar neurologic deficits, altered level of consciousness, nausea, and vomiting. Head injury and surgical procedures have been anecdotally reported to precipitate intracerebral hemorrhages, though a causal relationship remains to be established. Stronger evidence supports anticoagulant, thrombolytic, or antiplatelet agents as triggers for cerebral amyloid angiopathy-related hemorrhages (164; 123; 19). Individuals with exclusively lobar microbleeds may be at increased risk of incident intracerebral hemorrhage, even in the absence of prior intracerebral hemorrhage (183; 01); however, it is important to recognize that clinical context determines degree of risk (39). Hypertension frequently coexists with cerebral amyloid angiopathy in older populations. Growing evidence suggests that hypertension may increase risk of hemorrhage in cerebral amyloid angiopathy, but further studies in this area are required (16).

Other presentations. In addition to lobar hemorrhage, patients with sporadic cerebral amyloid angiopathy can present clinically with mild cognitive impairment or dementia (47; 26) as well as with transient focal neurologic episodes (TFNEs).

Cognitive impairment. Cognitive impairment and dementia are frequently encountered in patients with cerebral amyloid angiopathy. In Vinters’ series, over 40% of patients with cerebral amyloid angiopathy–related hemorrhage exhibited dementia (195). Dementia frequently occurs in patients after lobar intracerebral hemorrhage. Patients are at risk of developing dementia both immediately after intracerebral hemorrhage (early post-ICH dementia) and in the chronic phase, after hemorrhage (delayed post-ICH dementia). The yearly incidence of dementia appears to be 5.8% (95% CI: 5.1% to 7.0%). Larger hematoma size is associated with early risk but not late risk. Educational level, incident mood symptoms, and white matter disease appear to be associated with late-onset dementia (21). Although dementia might be triggered or exacerbated by the occurrence of cerebral amyloid angiopathy–related intracerebral hemorrhage, studies have suggested that as much as 24% of patients with cerebral amyloid angiopathy may have been cognitively impaired prior to hemorrhage (174; 12). Several studies have further suggested that the underlying small vessel disease in cerebral amyloid angiopathy, rather than the intracerebral hemorrhage itself, is a predictor of cognitive impairment in the disease (14; 18; 136). A study by Smith and colleagues also suggested that cerebral amyloid angiopathy–associated leukoaraiosis was an important mechanism for cognitive impairment in these subjects; severe white matter hyperintensities were present in 60% of subjects with pre-hemorrhage cognitive impairment versus 24% of those without. Along with leukoaraiosis, other mechanisms likely to contribute to cognitive impairment in cerebral amyloid angiopathy include lobar hemorrhages, microbleeds, ischemic infarcts, and parenchymal amyloid (ie, Alzheimer disease). Advanced cerebral amyloid angiopathy also appears to cause cognitive impairments in individuals without intracerebral hemorrhage. A clinical-pathological study of 404 community-dwelling individuals found that those with moderate to very severe cerebral amyloid angiopathy (79 of 404, 18.8%) had worse performance on measures of perceptual speed and episodic memory, even after controlling for potential confounders, such as age and Alzheimer disease pathology (05). A study has suggested that cerebral amyloid angiopathy is an important independent predictor of which patients with Alzheimer disease pathology go on to develop dementia. Patients with more severe cerebral amyloid angiopathy had faster rates of cognitive decline (27). Pathologic studies suggest that along with other age-related pathologies, cerebral amyloid angiopathy appears to be a frequent contributor to cognitive impairment in the elderly (28). The cognitive profile of patients with cerebral amyloid angiopathy resembles other types of vascular cognitive impairment, with most prominent deficits in executive function and processing speed (32; 206). Cognitive impairment in cerebral amyloid angiopathy is likely related to the accumulation of multiple pathologic lesions in the disease, including microbleeds, white matter hyperintensities, and cerebral microinfarctions (08; 07).

Transient focal neurologic episodes (TFNEs). Small hemorrhages or microbleeds in cerebral amyloid angiopathy occur in superficial sulcal/meningeal, cortical, and subcortical sites, most often without definite clinical manifestations. Some of these individuals, however, develop recurrent, transient neurologic symptoms (78; 154; 49). The symptoms are typically stereotyped, recurrent, transient neurologic events characterized by paresthesias, numbness, or weakness with a march over seconds or minutes (49; 139; 173). An analysis of 25 individuals with transient focal neurologic episodes from a multicenter cohort of 172 individuals diagnosed with cerebral amyloid angiopathy found approximately equal numbers with predominantly positive symptoms (spreading paresthesias, positive visual phenomena, or limb jerking) and negative symptoms (weakness, language impairment, or visual loss) (49). Among those individuals who underwent MRI, chronic superficial sulcal/meningeal hemorrhage was identified in 50% with transient focal neurologic episodes versus 19% without (p=0.001), suggesting a possible causative role for the superficial blood products in generating these symptoms. Acute convexity subarachnoid hemorrhage and cortical superficial siderosis could potentially trigger cortical spreading depolarizations, manifesting clinically as TFNEs (109). Importantly, these symptoms may be misdiagnosed as transient ischemic attacks, focal seizures, or migraine with aura. Neuroimaging, especially susceptibility-weighted MRI, might be warranted to ensure correct diagnosis (33; 106).

Several studies have shown an association between sulcal bleeding events and future intracerebral hemorrhage, raising the possibility that these spells might also be markers for future bleeding (49; 35; 13; 139; 162). In cohorts of patients with acute convexity subarachnoid hemorrhage and probable cerebral amyloid angiopathy, who predominantly presented with TFNEs, the rate of intracerebral hemorrhage was remarkably high, estimated in 19% per year (95% CI: 13% to 27%) (202; 33). Although antithrombotic treatment could reduce the risk of subsequent ischemic stroke in patients with transient ischemic attacks, it could exacerbate the hemorrhagic risk of patients with TFNEs related to cerebral amyloid angiopathy. Hence, the correct diagnosis of the underlying cause of neurologic symptoms is paramount (106).

Nonhemorrhagic imaging markers. Accumulating data suggest an association between cerebral amyloid angiopathy and white matter lesions or leukoaraiosis. Supporting lines of evidence include: (1) prominent leukoaraiosis in several hereditary forms of cerebral amyloid angiopathy (25; 70); (2) neuropathological correlations between advanced cerebral amyloid angiopathy and white matter disease (83); and (3) volumetric MRI analysis showing almost twice as much white matter disease in advanced cerebral amyloid angiopathy as in Alzheimer disease or mild cognitive impairment, conditions that are themselves associated with leukoaraiosis (82). The association between cerebral amyloid angiopathy and leukoaraiosis is striking, in that cerebral amyloid angiopathy generally spares the small vessels within the regions of white matter pallor. Topographically remote convexity or meningeal cerebral amyloid angiopathy have been suggested to generate leukoaraiosis indirectly by producing hypoperfusion of the white matter through long, pial-penetrating arteries (71). Like amyloid pathology in the disease, white matter lesions appear to have a posterior predominance in patients with cerebral amyloid angiopathy (178). The white matter lesion pattern of subcortical spots also appears to be more common in cerebral amyloid angiopathy compared to patients with hypertensive arteriopathy who more commonly harbor peribasal ganglia lesions (40). Hence, this multispot white matter hyperintensity pattern has been included in the updated Boston criteria v2.0 (34).

Cerebral amyloid angiopathy also appears to trigger small, clinically asymptomatic ischemic infarcts (189; 192). In a neuropathological study using microglial immunostaining to detect microinfarcts, these lesions were found to be significantly more common and more numerous in brains with severe rather than mild cerebral amyloid angiopathy (175). Analysis of living patients by diffusion-weighted MRI reached similar conclusions: small lesions consistent with subacute infarctions were identified in 12 of 78 (15%) with probable cerebral amyloid angiopathy versus 0 of 55 microbleed-free control subjects (99). The lesions were located mostly in cortex and subcortical white matter and were associated with higher numbers of cerebral microbleeds. An analysis of 114 patients with recent intracerebral hemorrhage found diffusion-weighted lesions in 9 of 39 (23%) with probable cerebral amyloid angiopathy versus 6 of 75 (8%) in other types of intracerebral hemorrhage and 0 of 47 age-matched control subjects (79), suggesting a particular association with advanced cerebral amyloid angiopathy. These diffusion-weighted lesions also appear to occur in cerebral amyloid angiopathy-related subarachnoid hemorrhages (13). A neuroimaging-neuropathological study has shown that the number of microbleeds on MRI correlates with the number of microinfarcts on pathology (108). An in-vivo-MRI-ex-vivo-MRI-histopathological approach revealed that DWI+ lesions are more common in cerebral amyloid angiopathy cases than in controls and represent acute microinfarcts (177).

Cortical microinfarctions may be an important contributor to cognitive impairment and dementia in cerebral amyloid angiopathy. A longitudinal study revealed that patients with cerebral amyloid angiopathy with cortical microinfarcts have a higher cumulative incidence of dementia than those without them (207). In a neuropathological study involving 284 autopsy cases of demented and nondemented individuals, the presence and severity of cerebral amyloid angiopathy was associated with microinfarcts comprising the CA1 region of the hippocampus and correlated with cognitive decline (87).

In concert, cerebral microinfarcts may disrupt structural connectivity networks in the brain, resulting in impairments in cognitive domains, such as executive functioning and processing speed, as well as reduced gait velocity (156). Furthermore, in patients followed longitudinally (mean follow-up time: 1.3±0.4 years), progression of impairment in structural connectivity networks was associated with worse executive functioning (Beta=0.41, p=0.04) (157).

Enlarged perivascular spaces (EPVS) are another neuroimaging marker of small vessel disease (SVD) (88; 166; 57; 214; 215; 199), and in cerebral amyloid angiopathy in particular (48; 121; 45). Previous studies on enlarged perivascular spaces have generally distinguished between enlarged perivascular spaces in the basal ganglia (BG-EPVS) and enlarged perivascular spaces in the white matter (WM-DPVS). Several studies have suggested that patients with probable or possible cerebral amyloid angiopathy appear to have a higher prevalence of severe enlarged perivascular spaces in the white matter (48; 121). Additionally, EPVS in the white matter appears to correlate with pathologically proven cerebral amyloid angiopathy (45). It has been hypothesized that in patients with cerebral amyloid angiopathy, interstitial fluid blockage due to amyloid beta accumulation within the perivascular space might favor the dilation of these spaces in white matter regions. This may be a result of changes in perivascular drainage due to aging and other factors that contribute to amyloid beta accumulation in patients with cerebral amyloid angiopathy (85). Indeed, neuropathologic evidence suggests that perivascular space dilatation is most severe in areas of high amyloid deposition (188). Furthermore, a neuroimaging-neuropathological study in cerebral amyloid angiopathy revealed that cortical arterioles overlying EPVS in the subcortical white matter have markedly reduced smooth muscle cells and increased vascular amyloid beta accumulation (147). Perivascular space dilatation may, thus, reflect impaired outward flow along arterioles, supporting the notion that perivascular clearance mechanisms are compromised in cerebral amyloid angiopathy.

Emerging nonhemorrhagic white matter MRI markers of cerebral amyloid angiopathy

(Contributed by Dr. Anand Viswanathan.)

Hereditary cerebral amyloid angiopathy. Several familial forms of cerebral amyloid angiopathy reported to date demonstrate autosomal dominant inheritance (15). The Icelandic form (hereditary cerebral hemorrhage with amyloidosis-Icelandic type) typically presents in the third decade with multiple intracerebral hemorrhages and progresses to dementia, paralysis, and early mortality (142). Headache (experienced in 63% of patients) and epilepsy (in 25%) are frequent. As opposed to other forms of cerebral amyloid angiopathy, most hemorrhages in the Icelandic form occur in the basal ganglia. Spinal cord vessels may also be affected. Survival is usually 10 to 20 years from symptom onset.

The Dutch form (Dutch-type hereditary cerebral amyloid angiopathy, also referred to as hereditary cerebral hemorrhage with amyloidosis-Dutch type) has been described in several families in two fishing villages on the North Sea coast of the Netherlands (213). This form of cerebral amyloid angiopathy has a later onset, in the fourth to sixth decades. Although chronic headaches may precede other symptoms by years, intracerebral hemorrhage is the usual presenting symptom. Another 13% of patients experience ischemic strokes, and white matter ischemic changes are common. Hemorrhages are frequently located in the parietal lobe and often progress. The mortality for the initial hemorrhage is 50% to 70% and is higher in females and when the disorder is paternally transmitted. Neuropsychiatric symptoms or dementia are a constant feature and likely represent a dementia predominantly of vascular etiology, although Alzheimer disease pathology may play a role in older subjects. The course can be varied, with some patients showing a relatively benign picture and others experiencing recurrent hemorrhages and death over a short period of time. White matter hyperintensities and cerebral microinfarctions appear to be more prevalent in presymptomatic subjects and may, thus, precede symptomatic intracerebral hemorrhage and cognitive symptoms (187). Evidence suggests that mutation carriers may have decreased levels of Aβ40 and Aβ42 in the CSF prior to the onset of clinical symptoms and, thus, may be an early biomarker in the disease (184). Decreased amyloid levels in the CSF are thought to be caused by increased vascular amyloid deposition in the disease, leading to vessel dysfunction. To further support this hypothesis, evidence suggests early changes in vascular reactivity in mutation carriers prior to symptom onset (185).

Several other hereditary forms of cerebral amyloid angiopathy have been identified. Continuing the convention of naming the forms according to the location where they were first observed, these include the Flemish, Italian, Arctic, Iowa, and Piedmont forms of hereditary cerebral amyloid angiopathy (213). Each of the forms has been reported to present clinically as either a dementing illness or lobar hemorrhage (with the exception of the Arctic form), with onset in approximately the sixth decade. The genetic basis for Dutch-type hereditary disease and these other forms of cerebral amyloid angiopathy is mutation in the amyloid precursor protein (APP) gene (see the paragraph on Genetics in the Pathogenesis and pathophysiology section of this article). Another set of families identified in France demonstrates a similar combination of dementia with or without hemorrhagic stroke, beginning in the fifth to sixth decade (167). Intriguingly, this hereditary form of disease appears related to duplication rather than mutation of amyloid precursor protein. The effect of gene dosage on amyloid deposition is similarly reflected by the noted association between Down syndrome and both Alzheimer disease and cerebral amyloid angiopathy. Anecdotal reports suggest older patients with Down syndrome are at increased risk of intracerebral hemorrhage (124), and cerebral amyloid angiopathy has been reported in patients with Down syndrome (129; 168). Because Alzheimer dementia develops universally in Down syndrome, it is difficult to determine the independent contribution of cerebral amyloid angiopathy to patients’ cognitive decline.

A British kindred has hereditary cerebral amyloid angiopathy that leads to progressive dementia, spasticity, and ataxia (familial British dementia, previously known as familial amyloidosis-British type) (194). Inheritance is autosomal dominant. In this form, the entire central nervous system is involved, including white matter, cerebellum, brainstem, and spinal cord. Age of onset is usually in the fifth or sixth decade. Unlike the Dutch and Icelandic forms, hemorrhage is not a prominent feature.

Familial oculoleptomeningeal amyloidosis is described in Japanese, Italian, and North American kindreds (181; 182). Clinical presentation varies from one kindred to another but can include dementia, ataxia, spasticity, ischemic strokes, seizures, peripheral neuropathy, hemiplegic migraine, myelopathy, blindness, and deafness. Intracerebral hemorrhage is rare. These patients have vascular amyloid deposition in the vitreous and retinal vessels, as well as in the leptomeningeal vessels and other organs, but not in brain parenchymal vessels.

Cerebral amyloid angiopathy-related inflammation. Growing numbers of patients have been reported to have episodes of inflammation associated with cerebral amyloid angiopathy (62; 170). These patients typically present with subacute mental status changes, headaches, and seizures, often at a slightly younger age than those presenting with cerebral amyloid angiopathy-related intracerebral hemorrhage. Characteristic imaging findings are prominent, asymmetric, white matter lesions with the MRI appearance of edema (hyperintense on T2-weighted sequences, increased diffusivity) that can extend to the overlying cerebral cortex (100). The clinical and neuroimaging criteria have a high sensitivity (82%) and specificity (95%) and can be used to make the diagnosis of cerebral amyloid angiopathy-related inflammation without brain biopsy (06).

Patients with this presentation often demonstrate clinical and neuroimaging improvement after immunosuppressive therapy, making this potentially the most therapeutically responsive subtype of cerebral amyloid angiopathy. The neuropathological appearance of cerebral amyloid angiopathy-related inflammation suggests that it represents an immune response to the vascular amyloid deposits. An autoimmune etiology has been further supported by the finding of high levels of antiamyloid autoantibodies in the cerebrospinal fluid of 10 individuals with probable cerebral amyloid angiopathy-related vascular inflammation (52) during the acute phase of the illness compared to several different control groups, including patients diagnosed with noninflammatory cerebra amyloid angiopathy or multiple sclerosis. As the patients with cerebral amyloid angiopathy-related inflammation entered remission after immunosuppressive treatment, autoantibodies returned to control levels (148).

Prognosis and complications

The outcome of acute lobar hemorrhage related to cerebral amyloid angiopathy is similar to that resulting from deep hemispheric hemorrhage related to hypertension. Both are associated with 3-month mortalities of approximately 25% and good outcomes (no or moderate disability) in only approximately 30% (163). Although lobar hemorrhage may be less likely than deep hemispheric hemorrhages to involve critical brainstem structures, this favorable feature is balanced by the tendency for lobar hemorrhages to be larger and to affect older patients.

Those who survive the initial hemorrhage remain at risk for recurrent hemorrhages, seizures, and cognitive deterioration. The cumulative rate of recurrent hemorrhage in survivors of lobar hemorrhage has been estimated at 21% over 2 years (141). Predictors of higher risk for recurrence are (1) history of a previous hemorrhage prior to the index presenting intracerebral hemorrhage; (2) possession of an apolipoprotein E2 or E4 allele (see Genetics subheading of Pathogenesis and pathophysiology section); (3) a larger number of hemorrhagic lesions counted on gradient-echo MRI scan; (4) presence of strictly lobar versus deep or mixed patterns of hemorrhage distribution (144); and (5) presence of cortical superficial siderosis (50; 105; 162; 26). In a study of 94 consecutive subjects with gradient-echo MRI at the time of lobar intracerebral hemorrhage, the 3-year cumulative risks for recurrent intracerebral hemorrhage were 14% for those with only one hemorrhage (ie, the presenting lesion) on MRI, 17% for those with two hemorrhagic lesions at baseline, 38% for those with three to five hemorrhages, and 51% for subjects with more than five hemorrhages (75).

Cortical superficial siderosis is considered one of the strongest predictors of first-ever and recurrent intracerebral hemorrhage and appears to also be associated with very early recurrent events in hemorrhage survivors (ie, recurrent event occurs within 6 months of index hemorrhage) (162). Multifocality, extent, and progression of cortical superficial siderosis have been associated with increased risk of recurrent hemorrhage (41; 150), with the annual incidence of intracerebral hemorrhage reaching 26.9% in those with bilateral disseminated cortical superficial siderosis (41). MRI and CT-visible convexity subarachnoid hemorrhage adjacent or remote from lobar acute intracerebral hemorrhage also herald an increased risk of recurrent bleeding (152; 112).

There is some evidence that posteriorly located white matter damage may increase intracerebral hemorrhage recurrence in patients with cerebral amyloid angiopathy (19). The presence of silent ischemic infarcts in the form of DWI+ lesions has also been associated with a higher number of total hemorrhages in patients with cerebral amyloid angiopathy (99). The presence of lacunes in individuals with cerebral amyloid angiopathy also relates to increased intracerebral hemorrhage risk (68).

Clinical vignette

A 65-year-old, right-handed man with history of multiple controlled vascular risk factors (diabetes mellitus, hypertension, hyperlipidemia) presented with acute onset of difficulty reading. He had a history of vague spells of word-finding difficulty in the previous year, as well as slightly increased forgetfulness, but remained fully functional and intellectually active. At the time of his symptoms, he was taking aspirin 81 mg daily, an oral hypoglycemic, an antihypertensive, and a statin. The family history was notable for dementia in the mother in her 70s and otherwise negative for stroke or other neurologic disease. Despite some ongoing complaints of mild difficulty reading, the neurologic exam showed no focal deficits and normal cognition, with zero errors on the Blessed Dementia Information-Memory-Concentration subscale.

Gradient-echo MRI sequences obtained after presentation demonstrated a subacute to chronic left occipital hematoma. These images also showed approximately 20 chronic hemorrhages or microbleeds, primarily in the left occipital and parietal lobes, but also involving the right occipital lobe. Moderately severe white matter hyperintensities were evident on T2-weighted sequences. There was no suggestion of mass lesion or vascular malformation underlying the hemorrhages, and a full laboratory examination disclosed no other cause of hemorrhage such as coagulopathy. The patient was diagnosed with probable cerebral amyloid angiopathy based on the finding of multiple strictly lobar hemorrhages without other definite cause.

The patient returned fully to his neurologic and functional baseline following his hemorrhagic stroke. Aspirin was stopped at the time of the acute hemorrhage but was restarted at 81 mg daily 2 weeks after presentation based on the presence of multiple vascular risk factors. The statin was continued for similar reasons. The antihypertensive medication was increased with the goal of bringing the blood pressure towards the low end of the normal range as tolerated. The patient was instructed not to use anticoagulants or drink heavily and otherwise to pursue his customary physical and mental activities.

Biological basis

Etiology and pathogenesis

	• Clinicopathologic studies suggest that patients with cerebral amyloid angiopathy may develop microvascular weakening due to deposition of amyloid in the microvasculature, which can lead to cerebral microbleeds, lobar hemorrhage, and subarachnoid hemorrhage.
	• Genetic forms of cerebral amyloid angiopathy are the subject of multiple ongoing studies and serve as a model for pathogenesis in sporadic amyloid angiopathy.

The underlying explanation for why particular individuals without family history develop amyloid beta deposition in cerebral blood vessels remains uncertain. In the absence of identified environmental risk factors, genetic factors seem likely, presumably multiple genes interacting in a complex manner. Supporting this possibility is the strong effect of family history on risk of lobar intracerebral hemorrhage (205). In hereditary cerebral amyloid angiopathy, genetic protein defects trigger the accumulation of beta-pleated sheet fibrils in cerebral vessels.

“Amyloid” is a general term for insoluble proteinaceous material composed of beta-pleated sheet fibrils. Different forms of amyloid occur in a variety of diseases and are deposited in different parts of the body; the beta-pleated sheet is a constant feature of all forms. Amyloids are typically resistant to proteolysis and have affinity for certain dyes. The predominant form of amyloid in sporadic cerebral amyloid angiopathy and the hereditary forms caused by mutation or duplication of amyloid precursor protein is the amyloid beta peptide.

Molecular biology. Amyloid beta protein (Aß) is a hydrophobic, nonglycosylated peptide of 39 to 43 amino acids derived from the amyloid precursor protein encoded by a 19-exon gene located on the long arm of chromosome 21.

Amyloid precursor protein, amyloid beta protein, and pathogenetic mutations

Location of genetic defects leading to some hereditary forms of cerebral amyloid angiopathy are shown. (Contributed by Dr. Jeffrey L Saver.)

The amyloid precursor protein is a 659- to 770-amino acid residue, membrane-associated glycoprotein processed by secretase enzymes to yield various fragments, including amyloid beta protein. Subtle biochemical differences distinguish the vascular amyloid of cerebral amyloid angiopathy from parenchymal amyloid deposits (eg, amyloid plaques in Alzheimer disease). Vascular amyloid is predominantly composed of the 39- to 40-amino acid amyloid beta protein species (Aß40), whereas parenchymal plaque amyloid is predominantly composed of a 42- to 43-amino acid amyloid beta protein species (Aß42).

Pathophysiology

Aggregation. The central pathophysiologic biochemical event in cerebral amyloid angiopathy is the aggregation of soluble subunit proteins into progressively larger, less soluble, and more biologically active structures. Studies of synthetic amyloid beta protein species demonstrate a tendency to self-aggregate to fibrils in vitro, a predilection more pronounced in Aß42 fragments than Aß40. Mutant peptides mimicking the codon 693 or 694 point mutation linked to the Dutch, Italian, Arctic, or Iowa types of hereditary cerebral hemorrhage with amyloidosis exhibit increased beta-sheet content, increased amyloidogenicity, and enhanced fibril stability. Factors favoring in vivo amyloid beta formation and deposition include (1) overproduction or increased levels of amyloid precursor (as in gene overdose in trisomy 21 Down disease or amyloid precursor protein duplication); (2) a highly amyloidogenic sequence (as in the codon 693 or 694 mutations); (3) altered proteolysis of the amyloid precursor (as in familial Alzheimer disease due to codon 692 mutation); (4) a seeding nucleation event analogous to seeding in crystal formation (132); (5) reduced clearance of brain amyloid (also suggested to occur with mutant forms of amyloid beta protein) (54); and (6) time. Finally, there is mounting evidence that decreases in cerebral blood flow could lead to increased amyloid deposition in cerebral amyloid angiopathy. This may be related to changes in amyloid clearance pathways associated with decreases in cerebral blood flow (66; 111).

Production and clearance of brain amyloid beta protein. A variety of theories regarding the source of cerebrovascular amyloid beta protein have been proposed over the years, including the possibility that it is derived from the systemic blood circulation or produced locally within brain blood vessels. There is some evidence that peripherally formed amyloid beta protein may influence cerebral amyloid deposition (60; 176). However, the prevailing model based on current data posits that amyloid beta protein is generated primarily by neurons, diffuses through the brain parenchyma (where it may deposit as the senile plaques of Alzheimer disease), and ultimately accompanies the brain interstitial fluid to the periarterial space (201). From the periarterial space, amyloid beta protein may either deposit within vessel walls as cerebral amyloid angiopathy or be cleared from the brain via efflux transport across the blood-brain barrier, proteolytic degradation, or centrifugal flow of interstitial fluid out of the brain (169; 24; 30; 135).

The following are among the experimental observations supporting this paradigm: (1) neuronal expression of amyloid precursor protein in transgenic mice is sufficient to produce robust cerebral amyloid angiopathy (demonstrating that amyloid beta protein produced by neurons can reach the vessels); (2) the earliest site of vascular amyloid beta protein deposition is located in proximity to the periarterial space, at the junction of the media and adventitia; (3) there is reduced clearance by efflux transport of the mutant forms of amyloid beta protein that tend to accumulate in vessels; (4) shifting the population of amyloid beta protein from Aß40 to Aß42 by coexpression of mutant presenilin-1 causes more of the peptide to deposit as senile plaques and less to reach the periarterial space and deposit in vessels (90); and (5) genetic reduction or elimination of the protease neprilysin causes cerebral amyloid angiopathy to appear in a transgenic mouse model that otherwise does not develop cerebral amyloid angiopathy at a comparable age (63).

Important implications of this model are that cerebral amyloid angiopathy progression might be slowed by agents that lower its production, decrease its tendency to aggregate in the periarterial space, stimulate its degradation, or enhance its clearance. Many of these predictions remain to be tested in mouse models and humans with cerebral amyloid angiopathy. Data testing an anti-amyloid immunotherapy in mice have suggested that it can both remove vascular amyloid deposits and improve vascular reactivity in animals (09). However, a phase 2 multicenter randomized control trial testing the effect of the same anti-amyloid immunotherapy on blood vessel function in patients with cerebral amyloid angiopathy showed that, though safe and well-tolerated, the drug was associated with a trend towards reduced cerebrovascular reactivity, opposite to the expected direction (http://clinicaltrials.gov/show/NCT01821118) (110).

Perivascular clearance has taken central stage in explaining the accumulation of amyloid beta in the brain and is considered an important shared pathogenic mechanism between Alzheimer disease and cerebral amyloid angiopathy (72). Although incompletely understood, perivascular drainage seems to be driven in part by arterial dilations, including both neurovascular coupling (91) and spontaneous vasomotion (72; 190). Evidence from studies in humans and animal models supports that vascular amyloid beta deposition interferes with cerebrovascular reactivity. Impaired perivascular clearance caused by vascular amyloid beta deposition could, thus, lead to a self-reinforcing cycle in which decreased perivascular clearance leads to accrued amyloid beta vascular accumulation and more damage to vascular structure and function (72). Reduced perivascular clearance of amyloid beta could also increase parenchymal amyloid beta accumulation. This hypothesis is supported by studies of patients participating in passive immunotherapy trials for Alzheimer disease. These studies suggest that by increasing the clearance of amyloid beta from plaques into the perivascular space, anti-amyloid immunotherapy could lead to an accumulation of vascular amyloid beta (24). More recently, the term amyloid-related imaging abnormalities (ARIA) was coined in relation to newer anti-amyloid immunotherapies. These include ARIA-E (edema) and ARIA-H (hemorrhage) and have imaging features that closely resemble cerebral amyloid angiopathy–related inflammation. Though incompletely understood, ARIA is thought to result from a combination of increased cerebral amyloid angiopathy in the setting of perivascular amyloid beta clearance as well as vascular amyloid beta removal leading to perivascular inflammation, blood-brain barrier leakage, and hemorrhage. Rapid mobilization of parenchymal amyloid beta from plaques into the vessel walls could also explain the reduction in cerebrovascular reactivity observed in patients with cerebral amyloid angiopathy treated with amyloid immunotherapy (110). Cerebral amyloid angiopathy has been identified as a significant risk factor for ARIA; therefore, leaders in the cerebral amyloid angiopathy research and clinical community have strongly recommended against the off-label use of currently available anti-amyloid immunotherapies for cerebral amyloid angiopathy (74).

There is mounting evidence that amyloid beta protein may propagate and accumulate in the central nervous system similar to prion proteins (86). Similar to prion proteins, amyloid beta protein has been detected in dura mater and pituitary glands. Furthermore, amyloid beta pathology has been replicated following amyloid beta inoculation in amyloid precursor protein (APP) transgenic mice, suggesting that amyloid beta pathology is transmissible, although unlike prion disease, there is no evidence that Alzheimer disease is transmissible (132; 60; 134; 209; 29). Numerous independent studies have reported significant amyloid beta pathology in cases of iatrogenic Creutzfeldt-Jakob disease either from cadaveric growth hormone injections or dura mater grafts (94; 65; 84; 160; 31; 58). The majority of cases in these studies demonstrate both parenchymal and vascular amyloid beta deposition (160; 31). One possible explanation for this is that both amyloid beta and prion protein seeds are transmitted during these procedures and propagate and accumulate in the brain concurrently. However, Ritchie and colleagues have observed amyloid protein accumulation even in the absence of prion protein in patients who received cadaveric growth hormone (160). Data from several groups have suggested that cerebral amyloid angiopathy itself may be transmissible through cadaveric dura matter exposure, termed “iatrogenic cerebral amyloid angiopathy” (89; 10). This is strong evidence that amyloid beta may have seeding properties that allows propagation and accumulation. In fact, the number of iatrogenic cerebral amyloid angiopathy cases reported in the literature has reached 49 (37), and diagnostic criteria have been proposed (11). Interestingly, cerebral vessels, rather than brain parenchymal, are the preferential site of amyloid beta propagation in iatrogenic cerebral amyloid angiopathy (37). The time interval between exposure and symptoms is estimated to be 3 to 4 decades, similar to the gap observed between initial detection of brain amyloid beta deposition in the form of reduced cerebrospinal fluid amyloid beta and first intracerebral hemorrhage among carriers of the Dutch-type hereditary cerebral amyloid angiopathy mutation (37; 103).

Pathogenesis of hemorrhage. Clinicopathologic studies identify several mechanisms through which patients with cerebral amyloid angiopathy may develop microvascular weakening leading to lobar and subarachnoid hemorrhage. Heavily amyloid-laden microvessels appear structurally brittle, with reduced fibrillary collagen in the vascular extracellular matrix, and potentially vulnerable to rupture (211). Maeda and colleagues found spindle-shaped microaneurysms in small cortical arteries with severe amyloid deposition (118). They suggested that (1) amyloid deposition leads to medial and adventitial damage; (2) vessel wall damage leads to microaneurysm formation; (3) plasma components invade the vessel wall leading to areas of fibrinoid necrosis; and (4) hemorrhage develops from rupture of microaneurysm. The finding by Vonsattel and colleagues that, among 17 brains with cerebral amyloid angiopathy, fibrinoid necrosis was present only in the 12 cases with hemorrhage supports the hypothesis that fibrinoid necrosis is the final common denominator determining whether hemorrhage will develop in cases of cerebral amyloid angiopathy (198). Of note, pathologic evidence demonstrates that vessel rupture sites associated with microbleeds, in fact, have no amyloid beta at the precise site of vessel rupture (191), supporting the concept that more than amyloid deposition alone is required to lead to vascular rupture. These vessels have evidence of local vascular remodeling, including fibrinoid necrosis. A neuropathological study examining vessel segments with evidence of vascular remodeling (including decreased vascular amyloid beta and fibrinoid necrosis) demonstrated that local perivascular inflammation was consistently observed surrounding these vessels (107). These findings suggest inflammation may be an essential component in the final steps preceding vascular rupture.

One additional mechanism by which amyloid beta protein may promote intracerebral hemorrhage is by increased local anticoagulant activity; fibrillar amyloid beta protein has been found to bind amyloid precursor protein and potentiate its inhibition of clotting factor XIa (200).

Genetics

Hereditary cerebral amyloid angiopathy. The hereditary cerebral amyloid angiopathies are all associated with alterations of the amyloid precursor protein gene. The gene for amyloid precursor protein resides on the long arm of chromosome 21 and contains 19 exons. The amyloid beta protein fragment of amyloid precursor protein is encoded by parts of exon 16 and 17. The Dutch, Flemish, Italian, Arctic, Iowa, and Piedmont forms of hereditary cerebral amyloid angiopathy are each associated with single nucleotide mutations within the amyloid beta protein-coding region of amyloid precursor protein, resulting in single amino acid changes in amyloid beta protein. The French hereditary form of cerebral amyloid angiopathy is associated with duplication of the amyloid precursor protein gene.

Cerebral amyloid angiopathy (inheritance and genetic defects)

Table shows inheritance and genetic defects of cerebral amyloid angiopathies. (Contributed by Dr. Chelsea S Kidwell.)

The location of the amyloid precursor protein mutations associated with prominent cerebral amyloid angiopathy contrasts with the amyloid precursor protein mutations associated primarily with familial Alzheimer disease, located immediately flanking rather than within the amyloid beta protein-coding regions. The majority of cases of familial Alzheimer disease are caused by defects in the presenilin genes located on chromosomes 14 (presenilin-1) and 1 (presenilin-2). Advanced cerebral amyloid angiopathy can occur in familial Alzheimer disease due to these gene defects but, in general, is not prominent.

Among nonamyloid beta protein forms of hereditary cerebral amyloid angiopathy, the Icelandic type of hereditary cerebral hemorrhage with amyloidosis is transmitted in autosomal dominant fashion. The cystatin C protein in affected patients lacks the first 10 amino acids and has a Glu-for-Leu substitution at residue 68. The gene for cystatin C lies on chromosome 20p11.2 and contains three exons. All patients with genetic analysis reported to date have demonstrated a single T-2-A transversion in codon 68. Familial oculoleptomeningeal amyloidosis is transmitted in autosomal dominant fashion. Like the more general class of familial amyloid polyneuropathies, these disorders are associated with mutations of the transthyretin gene located on chromosome 18. As multiple distinct transthyretin point mutations have been reported to associate with oculoleptomeningeal involvement in at least some families, the genotype-phenotype correlation of this spectrum of disorders remains to be worked out. However, patients with certain mutations that cause transthyretin amyloidosis develop cerebral amyloid angiopathy (171). Cerebral amyloid angiopathy may continue to develop in the brain in these patients even after therapeutic liver transplants because of choroid plexus production of variant amyloid. Maia and colleagues report a retrospective analysis of 87 consecutive posttransplant ATTR Val30Met FAP patients (119). They report that 31% of the patients developed cerebral amyloid angiopathy type symptoms including transient focal neurologic episodes, seizures, and hemorrhagic and ischemic stroke. Data from a cohort of subjects with most common Val30Met mutation of hereditary transthyretin amyloidosis (ATTR) suggest that cerebral amyloid angiopathy can be visualized in the brain in patients using Pittsburg compound B-based PET scans (172).

The genetic cause of familial British dementia has been identified as mutational loss of a stop codon within the BRI gene on chromosome 13 (194). The absence of the normal stop codon leads to generation of an insoluble 34 amino acid cleavage product that comprises the vascular amyloid deposits in this disorder. The early stages in the disease have been characterized. The most common MRI findings are extensive white matter hyperintensities. Infarction or atrophy of the corpus callosum was also frequently observed. Patients most commonly manifested isolated memory loss on neuropsychological testing. Spastic paraplegia and cerebellar ataxia are reported to be very common findings as the disease progresses (128).

Sporadic cerebral amyloid angiopathy. The major genetic risk factor for sporadic cerebral amyloid angiopathy (as well as sporadic Alzheimer disease) is the apolipoprotein E gene. Apolipoprotein E is located on chromosome 19q13.2 and exists in three major allelic variants differing by single nucleotide and amino acid differences: E2, E3, and E4. Both the apolipoprotein E2 and E4 alleles appear to increase the risk of cerebral amyloid angiopathy-related intracerebral hemorrhage. This situation contrasts with Alzheimer disease, where E4 increases risk but E2 decreases risk. The reason for this discrepancy may lie in differences between the cerebral amyloid angiopathy and Alzheimer disease processes: Apolipoprotein E4 enhances deposition of amyloid beta protein in both vessels and senile plaques, whereas apolipoprotein E2 may promote the breakdown of amyloid-laden vessels, a step that is unique to the cerebral amyloid angiopathy pathway (126). Pathologic studies have suggested that having the apolipoprotein E4 allele appears to increase severity of cerebral amyloid angiopathy (210). Although the apolipoprotein E2 genotype appears to be more common in cerebral amyloid angiopathy patients with intracerebral hemorrhage, the apolipoprotein E4 genotype is more common in patients with cognitive impairment (47).

A population-based study of hemorrhagic stroke in the greater Cincinnati/northern Kentucky region found possession of an E2 or E4 allele to confer 2.3-fold increased odds for lobar hemorrhage (205). The 29% attributable risk associated with apolipoprotein E genotype made it the single greatest attributable risk factor for lobar hemorrhage in this study. An analysis of 2189 individuals with intracerebral hemorrhage and 4041 control subjects drawn from seven international centers confirmed associations of lobar hemorrhage with apolipoprotein E2 (odds ratio 1.82) and E4 (odds ratio 2.2) at the extremely high levels of statistical significance typically used in genome-wide association studies (p< 1 x 10-9 for both alleles) (23). The same alleles are also associated with earlier hemorrhage recurrence. In a prospective study of 71 consecutive elderly patients who survived lobar hemorrhage, those who carried apolipoprotein E2 or E4 had a 2-year cumulative rate of recurrence of 28% compared to 10% for those with the common apolipoprotein E3/E3 genotype (141). The E2 allele further confers risk for larger hemorrhage volumes and worse outcomes following lobar intracerebral hemorrhage (17) suggesting specific effects of this genetic variant on the vascular structure in cerebral amyloid angiopathy.

Even adjusting for apolipoprotein E genotype, family history of hemorrhagic stroke remains another risk factor for lobar hemorrhage (205). A novel candidate genetic factor is the CR1 gene rs6656401 polymorphism, which was found to be associated with cerebral amyloid angiopathy-related lobar hemorrhage (odds ratio 1.61), risk of recurrent hemorrhage (hazard ratio 1.35), and severe cerebral amyloid angiopathy pathology at autopsy (odds ratio 1.34) (22). Heritability estimates suggest that, beyond the apolipoprotein E genotype, there is a substantial genetic contribution to risk of intracerebral hemorrhage in cerebral amyloid angiopathy (55). Future studies are, thus, likely to identify further genetic risks for sporadic cerebral amyloid angiopathy.

Neuropathology. Identification of cerebral amyloid angiopathy at autopsy is common in asymptomatic elderly individuals. Tomonaga found an incidence of 36% in an autopsy series of normal brains (179). The incidence of cerebral amyloid angiopathy in asymptomatic individuals increases with age. The prevalence of cerebral amyloid angiopathy pathology is even higher in the presence of accompanying Alzheimer disease (208). Cerebral amyloid angiopathy is noted in up to 92% of brains from patients with Alzheimer disease and is widely accepted as one of four microscopic features that, when present in abundance, allow for the neuropathologic diagnosis of Alzheimer disease. It is nonetheless important to note that cerebral amyloid angiopathy can occur without other Alzheimer pathologies, and Alzheimer disease can occur without evidence of cerebral amyloid angiopathy (27; 28). Patients with combined Alzheimer disease and cerebral amyloid angiopathy are at risk for lobar hemorrhage in addition to dementia. Evidence suggests that patients with Alzheimer disease and cerebral amyloid angiopathy appear to have an increased frequency of TFNEs (159). These symptoms might help identify patients with the disease without lobar hemorrhage in memory clinic populations. In a neuropathologic study of 117 brains with definite Alzheimer disease, the one quarter with moderate to severe cerebral amyloid angiopathy had a higher incidence of hemorrhages and ischemic lesions than those with less severe or absent cerebral amyloid angiopathy (61).

Cerebral amyloid angiopathy can be strongly suspected in brain tissue by examination of routine (hematoxylin- and eosin-stained) sections. Under routine staining, cerebral amyloid angiopathy appears in cortical microvessels as an effacement of the normal arteriolar smooth muscle cell component, which is replaced by a hyaline eosinophilic material. Its existence and extent can be confirmed by using cytochemical techniques, such as Congo red with polarization microscopy and thioflavin S or T with fluorescence microscopy. Although immunohistochemical techniques are more specific, conventional cytochemical methods (eg, Congo red) are still valuable tools for screening brain tissue removed at autopsy or biopsy for the presence of cerebral amyloid angiopathy.

Cerebral amyloid angiopathy in a patient with Alzheimer disease (photomicrograph)

Cerebral amyloid angiopathy (and senile plaques with amyloid cores) can be demonstrated using Congo red staining with polarization microscopy. Micrograph shows a Congo red-stained section from the brain of a patient with severe Al...

For definitive identification of cerebral amyloid angiopathy, histochemical methods have been largely superseded by immunohistochemical staining with primary antibodies to the major amyloid proteins: amyloid beta protein (for sporadic cerebral amyloid angiopathy or familial disease involving amyloid precursor protein mutation) or the specific protein deposits characteristic of other hereditary cerebral amyloid angiopathy syndromes such as transthyretin and cystatin C. Most antibodies work well in paraffin-embedded (therefore archival) material, and many primary antibodies are commercially available. Of interest is the observation that anti-cystatin C antibodies also show some labeling of vascular amyloid in sporadic cerebral amyloid angiopathy (196).

Alzheimer disease patient’s brain section

Alzheimer disease patient’s brain section is stained with an immunohistochemical method incorporating anti-amyloid beta protein (Aß) as primary antibody. Note strongly immunoreactive senile plaques, subpial immunoreactive Aß mater...
Hereditary cerebral hemorrhage with amyloidosis (brain section)

Section of brain from a patient with the Dutch type of hereditary cerebral hemorrhage with amyloidosis stained with anti-amyloid beta protein antibodies (in an immunohistochemical methodology) showing primarily immunoreactivity in...
Cerebral amyloid angiopathy in a patient with the Icelandic type of hereditary cerebral hemorrhage with amyloidosis

Section of brain from an affected patient double-labeled with antibodies to smooth muscle actin and cystatin C shows colocalization of signal within arteriolar smooth muscle cells. (Contributed by Dr. Jeffrey L Saver.)

Some patients with severe cerebral amyloid angiopathy develop superimposed cerebral amyloid angiopathy–related vascular remodeling, including microaneurysm formation, vessels with, a “lumen within lumen” appearance, and fibrinoid necrosis (120; 137).

Cerebral amyloid angiopathy-associated microangiopathy in patient with the Dutch type of hereditary cerebral hemorrhage with amyloidosis

Cerebral amyloid angiopathy-associated microangiopathy. Panel A shows arterial wall hyalinization (lower vessel) and ectasia with microaneurysm formation (upper vessel) in cerebellar meningeal arteries. (Contributed by Dr. Jeffrey...

Fibrinoid necrosis especially has been implicated in the occurrence of (fatal) cerebral amyloid angiopathy-related intracerebral hemorrhages (198). Ultrastructural studies of cerebral amyloid angiopathy, though few (because optimally preserved biopsy material is usually required for definitive interpretation of findings), show destruction of smooth muscle cells in affected arterioles, with deposition of characteristic 7 to 10 nm amyloid filaments in place of the smooth muscle and surrounding or encasing remaining smooth muscle cells. Surprisingly, the endothelium appears relatively normal in some instances of arteriolar cerebral amyloid angiopathy (197), though it may be severely damaged in the case of capillary amyloid deposition.

In cases of cerebral amyloid angiopathy-related inflammation, the vascular amyloid is associated with a perivascular inflammatory response or true transmural vasculitis, often of a giant-cell type. In these individuals, a variably severe granulomatous inflammatory response develops in response to the cerebral amyloid angiopathy. The inflammatory response includes macrophage and T-cell components (CD4+ and CD8+ cells), and both leptomeningeal and cortical parenchymal microvessels may be involved. Adjacent brain parenchyma usually shows infarcts or microhemorrhages.

Cerebral amyloid angiopathy associated with chronic granulomatous arteritis

Meningeal vessel shows severe transmural chronic inflammation, including multinucleated (foreign body type) giant cells that surround amyloid beta protein (Aß) immunoreactive material. One interpretation of this finding is that th...

In summary, based on the aforementioned spectrum of pathological changes related to cerebral amyloid angiopathy, neuropathology examination serves as the reference standard for the definite diagnosis of cerebral amyloid angiopathy. To this end, two main classification systems have been proposed. The most widely used in the clinical setting is a modified version of the 5-point cerebral amyloid angiopathy severity scale system proposed by Vonsattel and colleagues in 1991 (198; 77). In this scale, vessels in H&E and amyloid beta immunohistochemical staining sections are graded in the following way:

Grade 0 = absence of amyloid beta vascular staining
Grade 1 = presence of patchy amyloid beta vascular staining in an otherwise normal-appearing vessel
Grade 2 = thickened vessel wall, with media completely replaced by amyloid beta
Grade 3 = splitting of the vessel wall affecting at least 50% of vessel diameter in addition to the complete replacement of the media by amyloid beta, also known as “vessel-in-vessel” or “lumen-within-lumen” appearance
Grade 4 = amyloid beta–laden vessels with evidence of fibrinoid necrosis

The most advanced degree observed in leptomeningeal or parenchymal vessels defines the final grade. Grade 2 or greater in full brain autopsies and grade 1 or greater in brain biopsies or hematoma evacuations are considered diagnostic of cerebral amyloid angiopathy (36).

A new consensus protocol for neuropathological cerebral amyloid angiopathy assessment has been validated, and variations of this protocol are frequently used in research contexts (114). In this protocol, parenchymal and meningeal vessels are separately graded on a 0–3 scale in each lobe (0 = no amyloid beta, 1 = scant amyloid beta, 2 = some circumferential amyloid beta, and 3 = widespread circumferential amyloid beta); capillary cerebral amyloid angiopathy is defined as present or absent; and vasculopathy is graded on a 0–2 scale (0 = absent, 1 = occasional vessel, 2 = many vessels) (114).

Epidemiology

Primary intracerebral hemorrhages account for 10% of all strokes in Western populations and a higher proportion among Asians. Clinical and autopsy series from different populations suggest cerebral amyloid angiopathy is responsible for 10% to 34% of these intracerebral hemorrhages (92; 75). The mean age of patients with cerebral amyloid angiopathy-related hemorrhage is in the 70s.

The most important epidemiological risk factor for sporadic cerebral amyloid angiopathy is age. In an autopsy study of 128 subjects, Tomonaga found cerebral amyloid angiopathy in 8% of subjects in the seventh decade of life, 20% in the eighth, 37% in the ninth, and 58% in the tenth, with an overall incidence of 36% in normal subjects aged 60 to 97 (179). Other studies confirm the high prevalence in older individuals and that moderate to severe cerebral amyloid angiopathy is present in 66% of elders who were nondemented during life (05). Sporadic cerebral amyloid angiopathy is rarely seen in persons under 50 years old. There is no definite age-adjusted sex predilection of cerebral amyloid angiopathy. Some early studies reported a female predominance, but this likely reflected an older mean age of women in these series. With the exception of the hereditary forms of cerebral amyloid angiopathy, no evidence is seen of ethnic or geographic predilection.

Although cerebral amyloid angiopathy–related hemorrhage is not always associated with hypertension (205), antihypertensive treatment appears to reduce hemorrhage occurrence (204; 03). An observational study showed that elevated blood pressure is associated with increased recurrent lobar intracerebral hemorrhage risk in patients with probable or possible cerebral amyloid angiopathy (16). These results are in line with animal data suggesting that elevated blood pressure causes hemorrhage with decreased latency in amyloid transgenic mice compared to normal mice (146). A study demonstrated that total small vessel disease burden in cerebral amyloid angiopathy (approximated by combining the most common neuroimaging features in the disease) correlated with presence of vasculopathic changes on pathology (a hallmark sign of severity) and presentation with intracerebral hemorrhage (OR 2.40 [95% CI 1.06-5.45], p=0.035 and 2.23 [95%CI 1.07-4.64], p=0.033, respectively) (46). Neither diabetes mellitus nor coronary atherosclerosis, also prominent vascular risk factors, appears linked to cerebral amyloid angiopathy–related intracerebral hemorrhage. Other potential risks for lobar hemorrhage identified in epidemiological studies are previous ischemic stroke, frequent alcohol use, and low serum cholesterol. For the moment, it remains unclear whether these factors are associated cerebral amyloid angiopathy-related hemorrhages.

The role of genetic factors and family history as risks for cerebral amyloid angiopathy and lobar intracerebral hemorrhage is discussed in the Pathogenesis and pathophysiology section of this article.

Prevention

• Although there are no proven therapies available to prevent cerebral amyloid angiopathy, mounting evidence suggests that control of blood pressure may reduce the risk of recurrent intracerebral hemorrhage in the disease and potentially slow disease pathology.

In contrast to other forms of stroke, modifiable risk factors to prevent cerebral amyloid angiopathy–related outcomes have not been identified. Preliminary evidence suggests that in cerebral amyloid angiopathy patients with lobar intracerebral hemorrhage, elevated mean blood pressure predicts increased risk of intracerebral hemorrhage recurrence (16). Emerging evidence has linked increased blood pressure variability to elevated risk of cerebral small vessel disease, stroke, and dementia above and beyond the role of mean blood pressure levels. However, it remains unclear whether blood pressure variability may also contribute to subclinical disease course in cerebral amyloid angiopathy patients.

Preliminary evidence suggests that variability in blood pressure can influence tau burden in the brain (117). The total effect of blood pressure variability on cognitive progression was significantly mediated by both vascular pathology (defined as the summary score of microinfarcts, white matter rarefaction, atherosclerosis of the Circle of Willis, and arteriolosclerosis) and neurofibrillary tangle pathology (assessed by Braak stage), showing significant indirect effects. Additionally, the mediating role of putative ischemic vascular pathology appeared more pronounced among cognitively normal participants, whereas the mediating role of neurofibrillary tangles was strongly involved in both progression from normal cognition to mild cognitive impairment and dementia and from mild cognitive impairment to dementia. The data suggest that blood pressure variability may play a strong role in amyloid angiopathy–related cognitive impairment and disease pathology. Further studies are ongoing.

Differential diagnosis

The differential diagnosis for the intracerebral hemorrhage lesions associated with cerebral amyloid angiopathy includes the following:

• Malignant hypertension
• Hypertensive hemorrhage
• Arteriovenous malformations
• Cavernous hemangiomas
• Hemorrhage into cerebral neoplasms
• Trauma
• Vasculitis
• Coagulopathies
• Mycotic aneurysms
• Cerebral venous thrombosis
• Reversible cerebral vasoconstriction syndrome (RCVS)

The differential diagnosis for the advanced white matter disease that can result from cerebral amyloid angiopathy includes the following:

	• Hypertensive vasculopathy
	• Diffuse arteriosclerosis
	• Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
	• Fabry disease
	• Moyamoya disease
	• Fibromuscular dysplasia

Confusing conditions

The differential diagnosis of cerebral amyloid angiopathy–related hemorrhage includes the following:

	• Hypertensive-related hemorrhage, which can occur in lobar brain regions
	• Ischemic stroke with hemorrhagic transformation
	• Cerebral venous thrombosis–associated hemorrhage
	• Arteriovenous malformation–related brain hemorrhage
	• A hemorrhage-prone brain tumor

These diagnoses should be considered particularly when seeing patients of younger age (< 55 years old, consider arteriovenous or cavernous malformation–related hemorrhages, RCVS); patients with prodromal symptoms, such as headache (seen in cerebral venous thrombosis, RCVS); patients with stroke risk factors (atrial fibrillation, which may suggest ischemic stroke with hemorrhagic transformation); patients with poorly controlled hypertension or other vascular risk factors, such as diabetes (hypertensive-related hemorrhage); or patients with existing cancer (a metastatic hemorrhage–prone tumor to the brain). Neuroimaging features, including MRI and CT-based imaging, may help to further distinguish these possibilities. Angiography studies (CT and MRI angiograms or conventional angiography) may be able to help identify arteriovenous malformations.

Diagnostic workup

• MRI of the brain with gradient susceptibility imaging is the key test for identifying cerebral amyloid angiopathy. Cerebral amyloid angiopathy–related microbleeds and superficial sulcal and meningeal bleeding are sensitively detected by T2*-weighted gradient-echo or susceptibility-weighted imaging MRI techniques.

MRI and MRA scans add supportive evidence for the presence of cerebral amyloid angiopathy. MR images exclude an underlying tumor or vascular malformation more definitively than CT. Moreover, MRI allows the use of gradient refocused echo sequences (variously referred to as gradient-echo, magnetic susceptibility, or T2-weighted) that are particularly helpful because of their sensitivity to hemosiderin deposits from old hemorrhages, large or small.

Cerebral amyloid angiopathy (MRI)

MRI shows multiple cortical petechial hemorrhages on T2-weighted (top panels) and gradient refocused echo (bottom panels) sequences. Arrowheads indicate areas of hemosiderin deposition indicative of prior hemorrhage; arrows show e...

Gradient-echo MRI is particularly well suited to identify the multiple lobar hemorrhagic lesions required to meet the criteria for probable cerebral amyloid angiopathy and increase the level of diagnostic certainty (76). It should be noted that gradient-echo MRI is sensitive to deoxyhemoglobin as well as hemosiderin, making it an effective technique for the diagnosis of acute as well as chronic hemorrhage (98). Cerebral angiography does not aid the diagnosis of cerebral amyloid angiopathy except by more firmly ruling out other underlying vascular disorders. The presence of a “mixed” hemorrhagic pattern on gradient-echo MRI with regard to topographical distribution (ie, the coexistence of a lobar hemorrhage with deeply located cerebral microbleeds) remains a difficult clinical scenario with respect to diagnosing the predominant underlying small vessel disease (144; 180).

The diagnosis of cerebral amyloid angiopathy should be suspected in elderly individuals with symptomatic lobar intracerebral hemorrhage. The presence of strictly lobar cerebral microbleeds further increases the likelihood that advanced cerebral amyloid angiopathy is present. A definite diagnosis of cerebral amyloid angiopathy still requires a pathologic specimen. The Boston Criteria for diagnosis of cerebral amyloid angiopathy were designed to deal with this situation by recognizing various levels of diagnostic certainty (102). Diagnoses of definite cerebral amyloid angiopathy or probable cerebral amyloid angiopathy with supporting pathology, the highest levels of diagnostic certainty, require full postmortem exam showing pathologically severe cerebral amyloid angiopathy (for definite cerebral amyloid angiopathy) or a sample of brain tissue obtained by biopsy or hematoma evacuation showing some degree of cerebral amyloid angiopathy (for probable cerebral amyloid angiopathy) without other diagnostic lesion. In the more commonly encountered clinical situation in which brain tissue is unavailable, the in vivo diagnosis of probable cerebral amyloid angiopathy can be reached through a set of clinical and neuroimaging criteria, which have evolved over time. According to the first version of the Boston criteria (version 1.0), developed in the 1990s, multiple hemorrhages restricted to lobar regions in older individuals, not attributable to any other causes, were indicative of probable underlying cerebral amyloid angiopathy pathology in the absence of other definite causes of hemorrhage, such as head trauma or ischemic stroke, brain tumor, vascular malformation, vasculitis, blood dyscrasia, or coagulopathy (113). These criteria emanate from the most distinctive features of cerebral amyloid angiopathy-related hemorrhages: their tendency to be multiple, recurrent, and localized to cortical or corticosubcortical (ie, lobar) rather than deep hemispheric brain regions. In validating studies, 13 of 13 diagnoses of probable cerebral amyloid angiopathy were corroborated by neuropathologic exam, suggesting reasonably high specificity (102) and sensitivity was very high among clinically symptomatic patients known to carry the mutation for Dutch hereditary cerebral amyloid angiopathy (186). The diagnostic sensitivity of the Boston Criteria probable cerebral amyloid angiopathy category was further increased by including the presence of radiographically detected superficial sulcal/meningeal blood products as an additional site of bleeding when determining whether multiple hemorrhages are present (113), named the modified Boston criteria (version 1.5). The diagnosis of possible cerebral amyloid angiopathy is used for situations that are less suggestive, such as a single lobar hemorrhage without other definite cause.

Identification of probable or possible cerebral amyloid angiopathy depends on imaging of hemorrhages, which may be acute or chronic, and may represent sizable symptomatic hemorrhage or small (< 0.5 cm diameter) asymptomatic microbleeds. Acute lobar intracerebral hemorrhage is most commonly diagnosed with CT scan.

Cerebral amyloid angiopathy with lobar hemorrhage (CT)

CT showing lobar hemorrhage secondary to cerebral amyloid angiopathy (Contributed by Dr. Jeffrey L Saver.)

Validation of these criteria has been further extended to include patients with lobar microbleeds in the absence of intracerebral hemorrhage (122). It should be stated that although these criteria appear to have a high positive predictive value for cerebral amyloid angiopathy in patients with clinical symptoms, a study showed that microbleeds alone may have less predictive value for cerebral amyloid angiopathy in population-based cohorts (51).

To incorporate the more recently described and non-hemorrhagic white matter neuroimaging markers of cerebral amyloid angiopathy, named the enlarged perivascular spaces in the centrum semiovale and the multi-spot subcortical pattern of white matter hyperintensities, an updated version of the Boston criteria (version 2.0) has been proposed and validated among several multicenter cohorts of symptomatic individuals.

Table 1. Boston Criteria Version 2.0 For Diagnosis of Cerebral Amyloid Angiopathy

Definite cerebral amyloid angiopathy
	• Full postmortem brain examination showing the following:
		-- Spontaneous intracerebral hemorrhage, transient focal neurologic episodes, convexity subarachnoid hemorrhage, or cognitive impairment/dementia
		-- Severe cerebral amyloid angiopathy with vasculopathy
		-- Absence of another diagnostic lesion
Probable cerebral amyloid angiopathy with supporting pathology
	• Clinical data and pathologic tissue (evacuated hematoma or cortical biopsy) showing the following:
		-- Presentation with spontaneous intracerebral hemorrhage, transient focal neurologic episodes, convexity subarachnoid hemorrhage, or cognitive impairment/dementia
		-- Some degree of cerebral amyloid angiopathy in specimen
		-- Absence of another diagnostic lesion
Probable cerebral amyloid angiopathy
	• Clinical data and MRI demonstrating the following:
		-- Age ≥ 50 years
		-- Presentation with spontaneous intracerebral hemorrhage, transient focal neurologic episodes, convexity subarachnoid hemorrhage, or cognitive impairment/dementia
		-- Two or more of the following strictly lobar hemorrhagic lesions on T2*-weighted MRI, in any combination: intracerebral hemorrhage, cerebral microbleed, cortical superficial siderosis/convexity subarachnoid hemorrhage foci
		OR
		-- One lobar hemorrhagic lesion plus one white matter feature (severe CSO-EPVS or WMH-MS)
		-- Absence of any deep hemorrhagic lesions (intracerebral hemorrhage, cerebral microbleed) on T2*-weighted MRI
		-- Absence of another cause of hemorrhagic lesions.* Hemorrhagic lesions in cerebellum not counted as either lobar or deep hemorrhagic lesion.
Possible cerebral amyloid angiopathy
	• Clinical data and MRI demonstrating the following:
		-- Age ≥ 50 years
		-- Presentation with spontaneous intracerebral hemorrhage, transient focal neurologic episodes, convexity subarachnoid hemorrhage, or cognitive impairment/dementia
		-- One strictly lobar hemorrhagic lesion on T2*-weighted MRI, in any combination: intracerebral hemorrhage, cerebral microbleed, cortical superficial siderosis/convexity subarachnoid hemorrhage focus
		OR
		-- One white matter feature (severe CSO-EPVS or WMH-MS)
		-- Absence of any deep hemorrhagic lesions (intracerebral hemorrhage, cerebral microbleed) on T2*-weighted MRI
		-- Absence of another cause of hemorrhagic lesions.* Hemorrhagic lesions in cerebellum not counted as either lobar or deep hemorrhagic lesion.
Glossary: CSO-EPVS (enlarged perivascular spaces visible in the centrum semiovale), WMH-MS (white matter hyperintensities in a multi-spot subcortical pattern)
*Other causes of hemorrhagic lesion: antecedent head trauma, hemorrhagic transformation of an ischemic stroke, arteriovenous malformation, hemorrhagic tumor, central nervous system vasculitis
Modified from (34).

These new criteria showed superior accuracy compared to previous versions, improving diagnostic sensitivity without excessively compromising specificity. According to these new criteria, only one lobar hemorrhagic feature (either an intracerebral hematoma, a microbleed, or region of cortical superficial siderosis), in addition to either the presence of severe perivascular spaces in the centrum semiovale or the presence the multi-spot subcortical pattern of white matter hyperintensities, fulfills criteria for probable cerebral amyloid angiopathy in symptomatic individuals. According to these new criteria, the presence of two foci of cortical superficial siderosis also fulfills neuroimaging criteria for probable cerebral amyloid angiopathy. The presence of any deep hemorrhagic lesion remains a definite exclusion criterion in this updated version. It should be emphasized that none of the imaging findings included in the Boston criteria version 2.0 are perfectly sensitive or specific for cerebral amyloid angiopathy (37). Therefore, they should be interpreted in the intended clinical context. Patients must be over 50 years of age and present with either spontaneous intracerebral hemorrhage, TFNEs, cognitive impairment, or dementia to be eligible according to the Boston criteria v2.0. It remains unknown how these criteria perform in asymptomatic populations or in individuals with incidental findings (37).

CT-based criteria for making a diagnosis of cerebral amyloid angiopathy–associated lobar intracerebral hemorrhage in the acute setting have been suggested (the Edinburgh criteria) (161). Three predictors of cerebral amyloid angiopathy–associated lobar intracerebral hemorrhage diagnosis were included in two sets of rule-in or rule-out criteria: subarachnoid hemorrhage and finger-like projections from intracerebral hemorrhage on CT (among the most frequently reported CT features of cerebral amyloid angiopathy–associated lobar intracerebral hemorrhage in clinical routine) and APOE ε4 possession. In combination, these features appear to have strong predictive value for cerebral amyloid angiopathy (161). These criteria may be particularly useful in settings where MRI is scarcely available, such as low-to-middle income countries, and precisely where the incidence of intracerebral hemorrhages is higher (161). Because regular genetic testing is also unavailable worldwide, a simplified CT-based model of the Edinburgh criteria including only evidence of subarachnoid hemorrhage and finger-like projections and excluding APOE genotyping was tested and demonstrated high diagnostic accuracy (161). Patients who are not eligible for MRI, such as those with noncompatible hardware (eg, non-MRI conditional cardiac implantable electronic devices, metallic intraocular foreign bodies, drug infusion pumps, among others) may also benefit from the CT-based Edinburgh criteria.

The emerging approach of imaging amyloid beta deposits in vivo with high-affinity ligands developed for Alzheimer disease, such as the Pittsburgh compound B (PiB), has also been investigated in cerebral amyloid angiopathy (101). Two studies of PET imaging using Pittsburgh Compound B (PiB) performed on subjects with probable cerebral amyloid angiopathy found significantly increased PiB uptake relative to healthy elderly control subjects and a significantly elevated ratio of occipital-to-global PiB uptake relative to subjects with Alzheimer disease (97; 115). Concerning the value and accuracy of amyloid-PET in diagnosing patients with sporadic cerebral amyloid angiopathy, a meta-analysis reported a pooled sensitivity of 79% and specificity of 78% (35). Further studies have also indicated increased PiB retention at both current sites of cerebral amyloid angiopathy-related hemorrhagic lesions (56) and at sites of future bleeding in subjects who underwent follow-up MRI a median of 19 months after PiB-PET (81). The FDA-approved amyloid ligand Florbetapir has been shown to distinguish cerebral amyloid angiopathy-related hemorrhage from hypertensive hemorrhage, opening the question as to whether this tool could be used clinically to diagnosis cerebral amyloid angiopathy in select cases (80; 153). However, analyses could have been confounded by the concomitance of vascular and parenchymal amyloid due to the frequent coexistence of cerebral amyloid angiopathy and Alzheimer disease pathology. One study did not find evidence of regional cerebral amyloid angiopathy burden on pathology contributing to antemortem regional PiB-PET signal (127). In fact, among patients with minimal amyloid beta plaque pathology, no association was found between regional cerebral amyloid angiopathy and PiB-PET binding, suggesting that amyloid beta PET imaging is predominantly driven by parenchymal amyloid and is not likely a direct biomarker of cerebral amyloid angiopathy pathology. More studies are needed to better define the utility of amyloid beta PET imaging in cerebral amyloid angiopathy.

Neuropathological verification of cerebral amyloid angiopathy is most commonly accomplished by examination of tissue obtained from the wall of an evacuated lobar hematoma or postmortem exam. Brain biopsy is usually not pursued when clinical suspicion of cerebral amyloid angiopathy is high, as confirming a clinically probable diagnosis generally does not lead to major alterations in therapy. The exception to this situation is often those subjects with cerebral amyloid angiopathy-related inflammation, where biopsy can both establish a firm basis for immunosuppressive treatment and exclude other potential causes of brain inflammation. A brain specimen obtained for suspected cerebral amyloid angiopathy should include leptomeningeal tissue whenever possible. Brain tissue is examined by routine histologic stains (hematoxylin and eosin, Congo red) as well as immunostaining for amyloid beta protein, as indicated. In a study in which biopsy was simulated on postmortem brains with known cerebral amyloid angiopathy severity, the identification by Congo red staining of any degree of vascular amyloid in the biopsy specimen was highly sensitive for the diagnosis of definite cerebral amyloid angiopathy. The specificity for this diagnosis increased with greater severities of cerebral amyloid angiopathy in the biopsy specimen (77).

Cerebrospinal fluid markers may have an ancillary role in the diagnostic evaluation of cerebral amyloid angiopathy. In Alzheimer disease, analysis of cerebrospinal fluid has found Aß42 concentration to be lowered and concentration of the microtubule-associated protein tau to be elevated (53). Analysis of cerebrospinal fluid in 17 nondemented individuals with probable cerebral amyloid angiopathy found reduced concentrations of both Aß42 and Aß40 with normal or mildly increased tau (193). A meta-analysis suggests that decreased Aß40 levels can distinguish cerebral amyloid angiopathy from Alzheimer disease (43). Cerebrospinal fluid assays for Aß42 and tau are commercially available and may be considered when seeking confirmation of cerebral amyloid angiopathy.

Genetic testing in cerebral amyloid angiopathy is useful to identify mutations associated with one of the hereditary syndromes. Furthermore, APOE genotype analysis demonstrating at least one e4 allele (APOE e4) is strongly associated with moderate or severe cerebral amyloid angiopathy on pathology and has, thus, been incorporated in the Edinburgh criteria for in vivo diagnosis of cerebral amyloid angiopathy (161).

Cerebral amyloid angiopathy-related inflammation is associated with a distinct set of diagnostic findings. In addition to its defining neuropathologic appearance, this syndrome is also characterized by the striking MRI finding of asymmetric white matter hyperintensities involving periventricular and subcortical white matter and sometimes reaching the overlying cerebral cortex. Multiple lobar microbleeds are often present on gradient-echo sequences, not necessarily restricted to the cortical lobes affected by the T2 hyperintensities. Typically, minimal gadolinium enhancement is seen (although both leptomeningeal and parenchymal enhancement have been reported), with no diagnostic finding on MR-, CT-, or catheter-based angiography, presumably reflecting the small size of the inflamed vessels. An intriguing, though still unexplained, association has been noted between cerebral amyloid angiopathy-related inflammation and the apolipoprotein E4/E4 genotype (100).

Management

	• Blood pressure control is a key management step in patients with cerebral amyloid angiopathy.
	• Supportive ICU-level management for patients suffering intracerebral hemorrhage is recommended. Neurosurgical intervention may be performed in selective cases.
	• If possible, long-term anticoagulation should generally be avoided in patients who have suffered an intracerebral hemorrhage, although ongoing trials are investigating the role of anticoagulation.
	• Disease-modifying therapies are currently under investigation.

Management of acute lobar hemorrhage due to cerebral amyloid angiopathy is similar to hemorrhages of other etiologies. Previous studies suggested that evacuation could benefit patients with the lobar or superficial hemorrhages most commonly encountered in cerebral amyloid angiopathy (130; 131). Despite concerns that brain surgery might be especially hazardous in cerebral amyloid angiopathy because of an increased risk of perioperative bleeding, published series indicated that resections could be performed without elevated postoperative risk (133; 93; 212). The Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ENRICH) trial (NCT02880878), a multicenter adaptive trial, compared standard of care clinical management against early (< 24h) surgical hematoma evacuation through minimally invasive surgical procedures in patients with acute spontaneous, primary supratentorial intracerebral hemorrhage. This trial was the first to demonstrate the functional benefit of surgical hematoma evacuation. Surgical intervention was associated with improved functional outcome, measured using the modified Rankin scale, and lower 30-day mortality rates (results presented at the 2023 European Stroke Organization Conference). Current medical management for acute intracerebral hemorrhage includes blood pressure control, supportive medical care, discontinuation of antiplatelet agents, and reversal of anticoagulation. Osmotic agents and hyperventilation may be employed for temporary amelioration of raised intracranial pressure. The third multicenter Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3) demonstrated improved functional outcome for patients with acute intracerebral hemorrhage treated with a care bundle protocol that included early control of blood pressure, blood glucose, and body temperature and reversal of abnormal anticoagulation (116).

Currently, no active treatments for prevention of hemorrhage recurrence in cerebral amyloid angiopathy have been definitively established. However, some measures can reasonably be taken. Careful control of hypertension appears to be a prudent course in patients with cerebral amyloid angiopathy. This approach is supported by a secondary analysis of the Perindopril Protection against Recurrent Stroke Study (PROGRESS), in which stroke patients randomized to treatment with perindopril plus optional indapamide demonstrated lower risk of any intracerebral hemorrhage (50% risk reduction, 95% CI 26% to 67%) as well as specifically lower risk of intracerebral hemorrhages meeting criteria for probable cerebral amyloid angiopathy (77% risk reduction, 95% CI 19% to 93%) (03).

Anticoagulation increases both the likelihood and severity of hemorrhagic stroke and in general should be avoided in patients with cerebral amyloid angiopathy-related hemorrhage. Although data from randomized controlled trials are lacking, a decision-analysis model suggested that for patients with cerebral amyloid angiopathy-related hemorrhage, the increased risk of catastrophic recurrent hemorrhage associated with long-term anticoagulation outweighs the beneficial effects of preventing atrial fibrillation-related thromboembolic stroke (59). However, considering observational data suggesting that anticoagulation after intracerebral hemorrhage may be associated with improved outcomes (20) and equivocal data from SoSTART and APACHE-AF trials, future randomized controlled trials, including the ongoing ASPIRE trial (NCT03907046) and ENRICH-AF trial (NCT03950076), are required to definitively address this important issue (44). Antiplatelet agents may also increase the risk of hemorrhage, but the effect is likely substantially smaller. The RESTART trial randomized patients with recent intracerebral hemorrhage on aspirin for secondary prevention at the time of hemorrhage to continue aspirin or stop aspirin (158). No increase in the rates of major hemorrhage (including recurrent intracerebral hemorrhage) was observed. Therefore, it is a reasonable practice to consider continuing antiplatelet medications for secondary prevention and otherwise withhold them from patients with cerebral amyloid angiopathy–related hemorrhage. The risk of antiplatelet and anticoagulant therapy may be increased in the presence of an apolipoprotein E2 allele (125; 164). Similar questions have been raised about use of statin medications, which appear to increase the risk of hemorrhagic stroke (while decreasing the overall risk of stroke) when used for secondary stroke prevention (02; 69). The ongoing SATURN trial (NCT03936361) will help to clarify the safety of statins in this patient population. Prudent practice in treating patients with cerebral amyloid angiopathy is to use statins when clearly indicated for prevention of myocardial infarction or ischemic stroke but to withhold them in the absence of a definite indication.

Although immunosuppressive therapy has no established role for noninflammatory cerebral amyloid angiopathy, it leads to clinical and radiologic improvement in the majority of patients with the syndrome of cerebral amyloid angiopathy-related inflammation. In a follow-up study of 12 patients with cerebral amyloid angiopathy-related inflammation, 10 patients had initial improvement to immunosuppression but three of those 10 had subsequent relapse of symptoms, whereas the remaining two patients showed no response. The volume of T2 hyperintensities generally paralleled clinical improvements and subsequent relapses, making MRI a reasonable marker of treatment effect (138). Data also suggest that treatment of cerebral amyloid angiopathy–related inflammation with immunosuppression decreases relapse rates (155).

Reasonable choices for immunosuppressive regimen are a 5-day course of high-dose corticosteroids (500 mg-1 g/day x 5 days) followed by a slow PO steroid taper (over months). If there is no radiographic or clinical change, cyclophosphamide (1-2 mg/kg/day PO for 2 weeks) could be considered (consideration of brain biopsy to confirm diagnosis prior to initiating treatment is recommended). Other immunosuppressive agents may be further alternatives in high refractory cases, although clinical experience with these agents remains limited.

There are many exciting prospects for novel disease-modifying treatments for cerebral amyloid angiopathy. Cerebral amyloid angiopathy has a defined set of steps in its pathogenesis, including amyloid beta production, perivascular clearance of amyloid beta, vascular amyloid beta accumulation, vascular remodeling, and perivascular inflammation, each of which is a potential therapeutic target. Given improvements in identifying the presence and progression of cerebral amyloid angiopathy and the high volume of investigations into treatment approaches for amyloid beta protein-related disease, future years are likely to see multiple trials of biologically plausible candidate agents aimed at slowing this currently untreatable form of cerebrovascular disorder.

Media

References

01: Akoudad S, Portegies ML, Koudstaal PJ, et al. Cerebral microbleeds are associated with an increased risk of stroke: the Rotterdam Study. Circulation 2015;132(6):509-16. PMID 26137955
02: Amarenco P, Bogousslavsky J, Callahan A 3rd, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59. PMID 25341388
03: Arima H, Tzourio C, Anderson C, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke 2010;41(2):394-6. PMID 20044530
04: Arnason A. Apoplexie und ihre Verebung. Acta Psychiatr Neurol 1935;7:1-180.
05: Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011;69:320-7. PMID 21387377
06: Auriel E, Charidimou A, Gurol ME, et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol 2016;73(2):197-202. PMID 26720093
07: Auriel E, Edlow BL, Reijmer YD, et al Microinfarct disruption of white matter structure: a longitudinal diffusion tensor analysis. Neurology 2014;83(2):182-8. PMID 24920857
08: Auriel E, Greenberg SM. The pathophysiology and clinical presentation of cerebral amyloid angiopathy. Curr Atheroscler Rep 2012;14(4):343-50. PMID 22565298
09: Bales KR, O'Neill SM, Pozdnyakov N, et al. Passive immunotherapy targeting amyloid-beta reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain 2016;139(Pt 2):563-77. PMID 26493635
10: Banerjee G, Adams ME, Jaunmuktane Z, et al. Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Ann Neurol 2019;85(2):284-90. PMID 30597599
11: Banerjee G, Samra K, Adams ME, et al. Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. J Neurol Neurosurg Psychiatry 2022. [Epub ahead of print] PMID 35577510
12: Banerjee G, Wilson D, Werring DJ. Cognitive impairment before intracerebral hemorrhage is associated with cerebral amyloid angiopathy. Stroke 2018;49(1):40-5. PMID 29669878
13: Beitzke M, Enzinger C, Wunsch G, Asslaber M, Gattringer T, Fazekas F. Contribution of convexal subarachnoid hemorrhage to disease progression in cerebral amyloid angiopathy. Stroke 2015;46(6):1533-40. PMID 25953372
14: Benedictus MR, Hochart A, Rossi C, et al. Prognostic factors for cognitive decline after intracerebral hemorrhage. Stroke 2015;46(10):2773-8. PMID 26272386
15: Biffi A. Main features of hereditary cerebral amyloid angiopathies: a systematic review. Cereb Circ Cogn Behav 2022;3:100124. PMID 36324420
16: Biffi A, Anderson CD, Battey TW, et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA 2015;314(9):904-12. PMID 26325559
17: Biffi A, Anderson CD, Jagiella JM, et al. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol 2011;10:702-9. PMID 21741316
18: Biffi A, Bailey D, Anderson CD, et al. Risk factors associated with early vs delayed dementia after intracerebral hemorrhage. JAMA Neurol 2016a;73(8):969-76. PMID 27295605
19: Biffi A, Halpin A, Towfighi A, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010a;75(8):693-8. PMID 20733144
20: Biffi A, Kuramatsu JB, Leasure A, et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol 2017;82(5):755-65. PMID 29028130
21: Biffi A, Rattani A, Anderson CD, et al. Delayed seizures after intracerebral haemorrhage. Brain 2016b;139(Pt 10):2694-705. PMID 27497491
22: Biffi A, Shulman JM, Jagiella JM, et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology 2012;78(5):334-41. PMID 22262751
23: Biffi A, Sonni A, Anderson CD, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 2010b;68:934-43. PMID 21061402
24: Boche D, Zotova E, Weller RO, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008;131(Pt 12):3299-310. PMID 18953056
25: Bornebroek M, Haan J, van Buchem MA, et al. White matter lesions and cognitive deterioration in presymptomatic carriers of the amyloid precursor protein gene codon 693 mutation. Arch Neurol 1996;53:43-8. PMID 8599557
26: Boulouis G, Charidimou A, Jessel MJ, et al. Small vessel disease burden in cerebral amyloid angiopathy without symptomatic hemorrhage. Neurology 2017;88(9):878-84. PMID 28130469
27: Boyle PA, Yu L, Nag S, et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 2015;85(22):1930-6. PMID 26537052
28: Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol 2018;83(1):74-83. PMID 29244218
29: Burwinkel M, Lutzenberger M, Heppner FL, Schulz-Schaeffer W, Baier M. Intravenous injection of beta-amyloid seeds promotes cerebral amyloid angiopathy (CAA). Acta Neuropathol Commun 2018;6(1):23. PMID 29506560
30: Carare RO, Bernardes-Silva M, Newman TA, et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008;34(2):131-44. PMID 18208483
31: Cali I, Cohen ML, Halk S, et al. Iatrogenic Creutzfeldt-Jakob disease with amyloid-beta pathology: an international study. Acta Neuropathol Commun 2018;6(1):5. PMID 29310723
32: Case NF, Charlton A, Zwiers A, et al. Cerebral amyloid angiopathy is associated with executive dysfunction and mild cognitive impairment. Stroke 2016;47(8):2010-6. PMID 27338926
33: Charidimou A. Cerebral amyloid angiopathy-related transient focal neurological episodes (CAA-TFNEs): a well-defined clinical-radiological syndrome. J Neurol Sci 2019;406:116496. PMID 31703811
34: Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol 2022;21(8):714-25. PMID 35841910
35: Charidimou A, Farid K, Baron JC. Amyloid-PET in sporadic cerebral amyloid angiopathy: a diagnostic accuracy meta-analysis. Neurology 2017b;89(14):1490-8. PMID 28855406
36: Charidimou A, Frosch MP, Al-Shahi Salman R, et al. Advancing diagnostic criteria for sporadic cerebral amyloid angiopathy: study protocol for a multicenter MRI-pathology validation of Boston criteria v2.0. Int J Stroke 2019c;14(9):956-71. PMID 31514686
37: Charidimou A, Greenberg SM. Boston criteria version 2.0 and non-haemorrhagic presentations - Authors' reply. Lancet Neurol 2023;22(6):466-7. PMID 37210091
38: Charidimou A, Blacker D, Viswanathan A. Context is everything: From cardiovascular disease to cerebral microbleeds. Int J Stroke 2018a;13(1):6-10. PMID 28906204
39: Charidimou A, Boulouis G, Fotiadis P, et al. Acute convexity subarachnoid haemorrhage and cortical superficial siderosis in probable cerebral amyloid angiopathy without lobar haemorrhage. J Neurol Neurosurg Psychiatry 2018b;89(4):397-403. PMID 29054916
40: Charidimou A, Boulouis G, Haley K, et al. White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 2016a;86(6):505-11. PMID 26747886
41: Charidimou A, Boulouis G, Roongpiboonsopit D, et al. Cortical superficial siderosis multifocality in cerebral amyloid angiopathy: a prospective study. Neurology 2017a;89(21):2128-35. PMID 29070669
42: Charidimou A, Boulouis G, Xiong L, et al. Cortical superficial siderosis evolution. Stroke 2019a;50(4):954-62. PMID 30869563
43: Charidimou A, Farid K, Tsai HH, Tsai LK, Yen RF, Baron JC. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry 2018c;89(4):410-7. PMID 29070646
44: Charidimou A, Friedrich JO, Greenberg SM, Viswanathan A. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: a meta-analysis. Neurology 2018d;90(9):e754-e762. PMID 29386280
45: Charidimou A, Jaunmuktane Z, Baron JC, et al. White matter perivascular spaces: An MRI marker in pathology-proven cerebral amyloid angiopathy. Neurology 2014;82(1):57-62. PMID 24285616
46: Charidimou A, Martinez-Ramirez S, Reijmer YD, et al. Total magnetic resonance imaging burden of small vessel disease in cerebral amyloid angiopathy: an imaging-pathologic study of concept validation. JAMA Neurol 2016b;73(8):994-1001. PMID 27366898
47: Charidimou A, Martinez-Ramirez S, Shoamanesh A, et al. Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology 2015;84(12):1206-12. PMID 25716356
48: Charidimou A, Meegahage R, Fox Z, et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. J Neurol Neurosurg Psychiatry 2013a;84(6):624-9. PMID 23412074
49: Charidimou A, Peeters A, Fox Z, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke 2012;43(9):2324-30. PMID 22798323
50: Charidimou A, Peeters AP, Jager R, et al. Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology 2013b;81(19):1666-73. PMID 24107862
51: Charidimou A, Shoamanesh A, Al-Shahi Salman R, et al. Cerebral amyloid angiopathy, cerebral microbleeds and implications for anticoagulation decisions: the need for a balanced approach. Int J Stroke 2018e;13(2):117-20. PMID 29125055
52: Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry 2011;82(1):20-6. PMID 20935328
53: Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses. Arch Neurol 2003;60:1696-1702. PMID 14676043
54: Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004;43:333-44. PMID 15294142
55: Devan WJ, Falcone GJ, Anderson CD, et al. Heritability estimates identify a substantial genetic contribution to risk and outcome of intracerebral hemorrhage. Stroke 2013;44(6):1578-83. PMID 23559261
56: Dierksen GA, Skehan ME, Khan MA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 2010;68(4):545-8. PMID 20865701
57: Doubal FN, MacLullich AM, Ferguson KJ, Dennis MS, Wardlaw JM. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 2010;41(3):450-4. PMID 20056930
58: Duyckaerts C, Sazdovitch V, Ando K, et al. Neuropathy of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology. Acta Neuropathol 2018;135(2):201-12. PMID 29209767
59: Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage. A decision analysis. Stroke 2003;34:1710-6. PMID 12805495
60: Eisele YS, Obermuller U, Heilbronner G, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010;330(6006):980-2. PMID 20966215
61: Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer disease: the CERAD experience, Part XV. Neurology 1996;46:1592-6. PMID 8649554
62: Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004;55:250-6. PMID 14755729
63: Farris W, Schutz SG, Cirrito JR, et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 2007;171(1):241-51. PMID 17591969
64: Fischer O. Die presbyophrene Demenz, deren anatomische. Grundlage und Klinische Abgrenzung. Z Gesamte Neurol Psychiatr 1910;3:371-471.
65: Frontzek K, Lutz MI, Aguzzi A, Kovacs GG, Budka H. Amyloid-beta pathology and cerebral amyloid angiopathy are frequent in iatrogenic Creutzfeldt-Jakob disease after dural grafting. Swiss Med Wkly 2016;146:w14287. PMID 26812492
66: Garcia-Alloza M, Gregory J, Kuchibhotla KV, et al. Cerebrovascular lesions induce transient β-amyloid deposition. Brain 2011;134(Pt 12):3697-707. PMID 22120142
67: Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;122:1131-5. PMID 6375662
68: Gokcal E, Horn MJ, van Veluw SJ, et al. Lacunes, microinfarcts, and vascular dysfunction in cerebral amyloid angiopathy. Neurology 2021;96(12):e1646-54. PMID 33536272
69: Goldstein LB, Amarenco P, Szarek M, et al; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70(24 Pt 2):2364-70. PMID 18077795
70: Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001;49:697-705. PMID 11409420
71: Gray F, Dubas F, Roullet E, Escourolle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 1985;18:54-9. PMID 4037751
72: Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 2020;16(1):30-42. PMID 31827267
73: Greenberg SM, Charidimou A. Seed to bleed: iatrogenic cerebral amyloid angiopathy. Stroke 2023;54(5):1224-6. PMID 37035915
74: Greenberg SM, Cordonnier C, Schneider JA, et al. Off-label use of aducanumab for cerebral amyloid angiopathy. Lancet Neurol 2021;20(8):596-7. PMID 34237272
75: Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004;35:1415-20. PMID 15073385
76: Greenberg SM, Finklestein SP, Schaefer PW. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996;46:1751-4. PMID 8649586
77: Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997;28:1418-22. PMID 9227694
78: Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993;43:2073-9. PMID 8413970
79: Gregoire SM, Charidimou A, Gadapa N, et al. Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study. Brain 2011;134:2376-86. PMID 21841203
80: Gurol ME, Becker JA, Fotiadis P, et al. Florbetapir-PET to diagnose cerebral amyloid angiopathy: a prospective study. Neurology 2016;87(19):2043-9. PMID 27605173
81: Gurol ME, Dierksen G, Betensky R, et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 2012;79(4):320-6. PMID 22786597
82: Gurol ME, Irizarry MC, Smith EE, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;66:23-9. PMID 16401840
83: Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord 2002;14:161-6. PMID 12218260
84: Hamaguchi T, Taniguchi Y, Sakai K, et al. Significant association of cadaveric dura mater grafting with subpial Abeta deposition and meningeal amyloid angiopathy. Acta Neuropathol 2016;132(2):313-5. PMID 27314593
85: Hawkes CA, Jayakody N, Johnston DA, Bechmann I, Carare RO. Failure of perivascular drainage of β-amyloid in cerebral amyloid angiopathy. Brain Pathol 2014;24(4):396-403. PMID 24946077
86: Head MW, Ironside JW, Ghetti B, Jeffrey M, Pedro P, Will RG. Prion diseases. In: Love S, Perry A, Ironside JW, Budka H. Greenfield's Neuropathology. 9th ed. Boca Raton: CRC Press, 2015:1016-86.
87: Hecht M, Krämer LM, von Arnim CAF, Otto M, Thal DR. Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathol 2018;135(5):681-94. PMID 29574591
88: Heier LA, Bauer CJ, Schwartz L, Zimmerman RD, Morgello S, Deck MD. Large Virchow-Robin spaces: MR-clinical correlation. AJNR Am J Neuroradiol 1989;10(5):929-36. PMID 2505536
89: Herve D, Porche M, Cabrejo L, et al. Fatal Abeta cerebral amyloid angiopathy 4 decades after a dural graft at the age of 2 years. Acta Neuropathol 2018;135(5):801-3. PMID 29508058
90: Herzig MC, Van Nostrand WE, Jucker M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 2006;16:40-54. PMID 16612981
91: Holstein-Ronsbo S, Gan Y, Giannetto MJ, et al. Glymphatic influx and clearance are accelerated by neurovascular coupling. Nat Neurosci 2023;26(6):1042-53. PMID 37264158
92: Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 1993;116:135-41. PMID 8336159
93: Izumihara A, Ishihara T, Iwamoto N, Yamashita K, Ito H. Postoperative outcome of 37 patients with lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Stroke 1999;30:29-33. PMID 9880384
94: Jaunmuktane Z, Mead S, Ellis M, et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 2015;525(7568):247-50. PMID 26354483
95: Jellinger K. Cerebrovascular amyloidosis with cerebral hemorrhage. J Neurol 1977;214:195-206. PMID 65454
96: Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002;109:813-36. PMID 12111471
97: Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62(3):229-34. PMID 17683091
98: Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823-30. PMID 15494579
99: Kimberly WT, Gilson A, Rost NS, et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 2009;72:1230-5. PMID 19349602
100: Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007;68(17):1411-6. PMID 17452586
101: Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19. PMID 14991808
102: Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537-9. PMID 11222803
103: Koemans EA, Chhatwal JP, van Veluw SJ, et al. Progression of cerebral amyloid angiopathy: a pathophysiological framework. Lancet Neurol 2023;22(7):632-42. PMID 37236210
104: Koemans EA, Voigt S, Rasing I, et al. Cerebellar superficial siderosis in cerebral amyloid angiopathy. Stroke 2022;53(2):552-7. PMID 34538086
105: Koo HW, Jo KI, Yeon JY, Kim JS, Hong SC. Clinical features of high-degree centrum semiovale-perivascular spaces in cerebral amyloid angiopathy. J Neurol Sci 2016;367:89-94. PMID 27423569
106: Kozberg M, Perosa V, Gurol ME, van Veluw SJ. A practical approach to the management of cerebral amyloid angiopathy. Int J Stroke 2021;16(4):356-69. PMID 33252026
107: Kozberg MG, Yi I, Freeze WM, et al. Blood-brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy. Brain Commun 2022;4(5):fcac245. PMID 36267331
108: Lauer A, van Veluw SJ, William CM, et al. Microbleeds on MRI are associated with microinfarcts on autopsy in cerebral amyloid angiopathy. Neurology 2016;87(14):1488-92. PMID 27613583
109: Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab 2011;31(1):17-35. PMID 21045864
110: Leurent C, Goodman JA, Zhang Y, et al. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. Ann Clin Transl Neurol 2019;6(4):795-806. PMID 31020004
111: Li H, Guo Q, Inoue T, et al. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener 2014;9:28. PMID 25108425
112: Li Q, Zanon Zotin MC, Warren AD, et al. CT-visible convexity subarachnoid hemorrhage is associated with cortical superficial siderosis and predicts recurrent ICH. Neurology 2021;96(7):e986-94. PMID 33087495
113: Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010;74(17):1346-50. PMID 20421578
114: Love S, Chalmers K, Ince P, et al. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis 2014;3(1):19-32. PMID 24754000
115: Ly JV, Donnan GA, Villemagne VL, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010;74(6):487-93. PMID 20142615
116: Ma L, Hu X, Song L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet 2023;402(10395):27-40. PMID 37245517
117: Ma Y, Blacker D, Viswanathan A, et al. Visit-to-visit blood pressure variability, neuropathology, and cognitive function. Neurology 2021;96(23):e2812-3. PMID 33903194
118: Maeda A, Yamada M, Itoh Y, Otomo E, Hayakawa M, Miyatake T. Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy. Stroke 1993;24:1857-64. PMID 8248968
119: Maia LF, Magalhaes R, Freitas J, et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry 2015;86(2):159-67. PMID 25091367
120: Mandybur TI. Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol 1986;45:79-90. PMID 3941328
121: Martinez-Ramirez S, Pontes-Neto OM, Dumas AP, et al. Topography of dilated perivascular spaces in subjects from a memory clinic cohort. Neurology 2013;80(17):1551-6. PMID 23553482
122: Martinez-Ramirez S, Romero JR, Shoamanesh A, et al. Diagnostic value of lobar microbleeds in individuals without intracerebral hemorrhage. Alzheimers Dement 2015;11(12):1480-8. PMID 26079413
123: McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 2004;3:484-92. PMID 15261609
124: McCarron MO, Nicoll JA, Graham DI. A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors. J Neurol Neurosurg Psychiatry 1998;65:405-6. PMID 9728967
125: McCarron MO, Nicoll JA, Ironside JW, et al. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE epsilon 2 with putative clinical risk factors. Stroke 1999b;30:1643-6. PMID 10436115
126: McCarron MO, Nicoll JA, Stewart J, et al. The apoliprotein E epsilon 2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropath Exp Neurol 1999a;58:711-8. PMID 10411341
127: McCarter SJ, Lesnick TG, Lowe V, et al. Cerebral amyloid angiopathy pathology and its association with amyloid-β PET signal. Neurology 2021;97(18):e1799-808. PMID 34504022
128: Mead S, James-Galton M, Revesz T, et al. Familial British dementia with amyloid angiopathy: early clinical, neuropsychological and imaging findings. Brain 2000;123(Pt 5):975-91. PMID 10775542
129: Mendel T, Bertrand E, Szpak GM, Stepien T, Wierzba-Bobrowicz T. Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome - a case report. Folia Neuropathol 2010;48(3):206-11. PMID 20925005
130: Mendelow AD, Gregson BA, Fernandes HM, et al; STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005;365:387-97. PMID 15680453
131: Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013;382(9890):397-408. PMID 23726393
132: Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006;313:1781-4. PMID 16990547
133: Minakawa T, Takeuchi S, Sasaki O, et al. Surgical experience with massive lobar haemorrhage caused by cerebral amyloid angiopathy. Acta Neurochir (Wien) 1995;132:48-52. PMID 7754858
134: Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-beta deposition in vivo. Mol Psychiatry 2012;17(12):1347-53. PMID 21968933
135: Morris AW, Sharp MM, Albargothy NJ, et al. Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol 2016;131(5):725-36. PMID 26975356
136: Moulin S, Labreuche J, Bombois S, et al. Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study. Lancet Neurol 2016;15(8):820-9. PMID 27133238
137: Natte R, Vinters HV, Maat-Schieman ML, et al. Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Stroke 1998;29:1588-94. PMID 9707198
138: Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357(9251):169-75. PMID 11213093
139: Ni J, Auriel E, Jindal J, et al. The characteristics of superficial siderosis and convexity subarachnoid hemorrhage and clinical relevance in suspected cerebral amyloid angiopathy. Cerebrovasc Dis 2015a;39(5-6):278-86. PMID 25871492
140: Ni J, Auriel E, Martinez-Ramirez S, et al. Cortical localization of microbleeds in cerebral amyloid angiopathy: an ultra high-field 7T MRI study. J Alzheimers Dis 2015b;43(4):1325-30. PMID 25171715
141: O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000;342:240-5. PMID 10648765
142: Palsdottir A, Snorradottir AO, Thorsteinsson L. Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. Brain Pathol 2006;16:55-9. PMID 16612982
143: Pardridge WM, Vinters HV, Yang J, et al. Amyloid angiopathy of Alzheimer’s disease: amino acid composition and partial sequence of a 4,200-dalton peptide isolated from cortical microvessels. J Neurochem 1987;49:1394-401. PMID 3312495
144: Pasi M, Charidimou A, Boulouis G, et al. Mixed-location cerebral hemorrhage/microbleeds: underlying microangiopathy and recurrence risk. Neurology 2018;90(2):e119-26. PMID 29247070
145: Pasi M, Pongpitakmetha T, Charidimou A, et al. Cerebellar microbleed distribution patterns and cerebral amyloid angiopathy. Stroke 2019;50(7):1727-33. PMID 31159702
146: Passos GF, Kilday K, Gillen DL, Cribbs DH, Vasilevko V. Experimental hypertension increases spontaneous intracerebral hemorrhages in a mouse model of cerebral amyloidosis. J Cereb Blood Flow Metab 2016;36(2):399-404. PMID 26661173
147: Perosa V, Oltmer J, Munting LP, et al. Perivascular space dilation is associated with vascular amyloid-β accumulation in the overlying cortex. Acta Neuropathol 2022;143(3):331-48. PMID 34928427
148: Piazza F, Greenberg SM, Savoiardo M, et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 2013;73(4):449-58. PMID 23625526
149: Pichler M, Vemuri P, Rabinstein AA, et al. Prevalence and natural history of superficial siderosis: a population-based study. Stroke 2017;48(12):3210-4. PMID 29070715
150: Pongpitakmetha T, Fotiadis P, Pasi M, et al. Cortical superficial siderosis progression in cerebral amyloid angiopathy: prospective MRI study. Neurology 2020;94(17):e1853-65. PMID 32284360
151: Raposo N, Calviere L, Cazzola V, et al. Cortical superficial siderosis and acute convexity subarachnoid hemorrhage in cerebral amyloid angiopathy. Eur J Neurol 2018;25(2):253-9. PMID 29053885
152: Raposo N, Charidimou A, Roongpiboonsopi D, et al. Convexity subarachnoid hemorrhage in lobar intracerebral hemorrhage: a prognostic marker. Neurology 2020;94(9):e968-77. PMID 32019785
153: Raposo N, Planton M, Peran P, et al. Florbetapir imaging in cerebral amyloid angiopathy-related hemorrhages. Neurology 2017;89(7):697-704. PMID 28724587
154: Raposo N, Viguier A, Cuvinciuc V, et al. Cortical subarachnoid haemorrhage in the elderly: a recurrent event probably related to cerebral amyloid angiopathy. Eur J Neurol 2011;18:597-603. PMID 21040231
155: Regenhardt RW, Thon JM, Das AS, et al. Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation. JAMA Neurol 2020;77(10):1261-9. PMID 32568365
156: Reijmer YD, Fotiadis P, Martinez-Ramirez, et al. Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain 2015;138(Pt 1):179-88. PMID 25367025
157: Reijmer YD, Fotiadis P, Riley GA, et al. Progression of brain network alterations in cerebral amyloid angiopathy. Stroke 2016;47(10):2470-5. PMID 27576378
158: RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet 2019;393(10191):2613-23. PMID 31128924
159: Ringman JM, Sachs MC, Zhou Y, Monsell SE, Saver JL, Vinters HV. Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol 2014;71(7):878-83. PMID 24797962
160: Ritchie DL, Adlard P, Peden AH, et al. Amyloid-beta accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathol 2017;134(2):221-40. PMID 28349199
161: Rodrigues MA, Samarasekera N, Lerpiniere C, et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol 2018;17(3):232-40. PMID 29331631
162: Roongpiboonsopit D, Charidimou A, William CM, et al. Cortical superficial siderosis predicts early recurrent lobar hemorrhage. Neurology 2016;87(18):1863-70. PMID 27694268
163: Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4. PMID 15111374
164: Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000;55:947-51. PMID 11061249
165: Rosand J, Muzikansky A, Kumar A, et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol 2005;58:459-62. PMID 16130107
166: Rouhl RP, van Oostenbrugge RJ, Knottnerus IL, Staals JE, Lodder J. Virchow-Robin spaces relate to cerebral small vessel disease severity. J Neurol 2008;255(5):692-6. PMID 18286319
167: Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24-6. PMID 16369530
168: Sabbagh MN, Fleisher A, Chen K, et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. Arch Neurol 2011;68(11):1461-6. PMID 22084131
169: Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol 2006;238(4): 962-74. PMID 16112683
170: Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005;128:500-15. PMID 15659428
171: Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015;86(9):1036-43. PMID 25604431
172: Sekijima Y, Yazaki M, Oguchi K, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology 2016;87(8):773-81. PMID 27466465
173: Smith EE, Charidimou A, Ayata C, Werring DJ, Greenberg SM. Cerebral amyloid angiopathy-related transient focal neurologic episodes. Neurology 2021;97(5):231-8. PMID 34016709
174: Smith EE, Gurol ME, Eng JA, et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 2004;63:1606-12. PMID 15534243
175: Soontornniyomkij V, Lynch MD, Mermash S, et al. Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol 2010;20(2):459-67. PMID 19725828
176: Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS. Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. J Neurosci Res 2011;89(6):808-14. PMID 21374699
177: Ter Telgte A, Scherlek AA, Reijmer YD, et al. Histopathology of diffusion-weighted imaging-positive lesions in cerebral amyloid angiopathy. Acta Neuropathol 2020;139(5):799-812. PMID 32108259
178: Thanprasertsuk S, Martinez-Ramirez S, Pontes-Neto OM, et al. Posterior white matter disease distribution as a predictor of amyloid angiopathy. Neurology 2014;83(9):794-800. PMID 25063759
179: Tomonaga M. Cerebral amyloid angiopathy in the elderly. J Am Geriatr Soc 1981;29:151-7. PMID 7204810
180: Tsai HH, Pasi M, Tsai LK, et al. Microangiopathy underlying mixed-location intracerebral hemorrhages/microbleeds: a PiB-PET study. Neurology 2019;92(8):e774-81. PMID 30674594
181: Uitti RJ, Donat JR, Rozdilsky B, Scheider RJ, Koeppen AH. Familial oculoleptomeningeal amyloidosis. Arch Neurol 1988;45:1118-22. PMID 3178532
182: Ushiyama M, Ikeda S, Yanagisawa N. Transthyretin-type cerebral amyloid angiopathy in type I familial amyloid polyneuropathy. Acta Neuropathol 1991;81(5):524-8. PMID 1858483
183: van Etten ES, Auriel E, Haley KE, et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke 2014;45(8):2280-5. PMID 24947286
184: van Etten ES, Verbeek MM, van der Grond J, et al. β-Amyloid in CSF: biomarker for preclinical cerebral amyloid angiopathy. Neurology 2017;88(2):169-76. PMID 27903811
185: van Opstal AM, van Rooden S, van Harten T, et al. Cerebrovascular function in presymptomatic and symptomatic individuals with hereditary cerebral amyloid angiopathy: a case-control study. Lancet Neurol 2017;16(2):115-22. PMID 27989553
186: van Rooden S, van der Grond J, van den Boom R, et al. Descriptive analysis of the Boston criteria applied to a Dutch-type cerebral amyloid angiopathy population. Stroke 2009;40:3022-7. PMID 19556530
187: van Rooden S, van Opstal AM, Labadie G, et al. Early magnetic resonance imaging and cognitive markers of hereditary cerebral amyloid angiopathy. Stroke 2016;47(12):3041-4. PMID 27834748
188: van Veluw SJ, Biessels GJ, Bouvy WH, et al. Cerebral amyloid angiopathy severity is linked to dilation of juxtacortical perivascular spaces. J Cereb Blood Flow Metab 2016a;36(3):576-80. PMID 26661250
189: van Veluw SJ, Charidimou A, van der Kouwe AJ, et al. Microbleed and microinfarct detection in amyloid angiopathy: a high-resolution MRI-histopathology study. Brain 2016b;139(Pt 12):3151-62. PMID 27645801
190: van Veluw SJ, Hou SS, Calvo-Rodriguez M, et al. Vasomotion as a driving force for paravascular clearance in the awake mouse brain. Neuron 2020;105(3):549-61.e5. PMID 31810839
191: van Veluw SJ, Scherlek AA, Freeze WM, et al. Different microvascular alterations underlie microbleeds and microinfarcts. Ann Neurol 2019;86(2):279-92. PMID 31152566
192: van Veluw SJ, Kuijf HJ, Charidimou A, et al. Reduced vascular amyloid burden at microhemorrhage sites in cerebral amyloid angiopathy. Acta Neuropathol 2017a;133(3):409-15. PMID 27771772
193: Verbeek MM, Kremer BP, Rikkert MO, et al. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 2009;66:245-9. PMID 19743453
194: Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999;399:776-81. PMID 10391242
195: Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987;18:311-24. PMID 3551211
196: Vinters HV, Secor DL, Pardridge WM, Gray F. Immunohistochemical study of cerebral amyloid angiopathy. III. Widespread Alzheimer A4 peptide in cerebral microvessel walls colocalizes with gamma trace in patients with leukoencephalopathy. Ann Neurol 1990;28:34-42. PMID 2197973
197: Vinters HV, Secor DL, Read SL, et al. Microvasculature in brain biopsy specimens from patients with Alzheimer’s disease: an immunohistochemical and ultrastructural study. Ultrastruct Pathol 1994;18:333-48. PMID 8066824
198: Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991;30:637-49. PMID 1763890
199: Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12(8):822-38. PMID 23867200
200: Wagner MR, Keane DM, Melchor JP, Auspaker KR, Van Nostrand WE. Fibrillar amyloid beta-protein binds protease nexin-2/amyloid beta-protein precursor: stimulation of its inhibition of coagulation factor XIa. Biochemistry 2000;39:7420-7. PMID 10858290
201: Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153:725-33. PMID 9736023
202: Wilson D, Hostettler IC, Ambler G, Banerjee G, Jager HR, Werring DJ. Convexity subarachnoid haemorrhage has a high risk of intracerebral haemorrhage in suspected cerebral amyloid angiopathy. J Neurol 2017;264(4):664-73. PMID 28154972
203: Wollenweber FA, Baykara E, Zedde M, et al. Cortical superficial siderosis in different types of cerebral small vessel disease. Stroke 2017;48(5):1404-7. PMID 28364025
204: Woo D, Kaushal R, Chakraborty R, et al. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke 2005;36:1874-9. PMID 16100021
205: Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 2002;33:1190-6. PMID 11988589
206: Xiong L, Davidsdottir S, Reijmer YD, et al. Cognitive profile and its association with neuroimaging markers of non-demented cerebral amyloid angiopathy patients in a stroke unit. J Alzheimers Dis 2016;52(1):171-8. PMID 27060947
207: Xiong L, van Veluw SJ, Bounemia N, et al. Cerebral cortical microinfarcts on magnetic resonance imaging and their association with cognition in cerebral amyloid angiopathy. Stroke 2018;49(10):2330-6. PMID 30355109
208: Yamada M, Tsukagoshi H, Otomo E, Hayakawa M. Cerebral amyloid angiopathy in the aged. J Neurol 1987;234:371-6. PMID 3655840
209: Ye L, Fritschi SK, Schelle J, et al. Persistence of Abeta seeds in APP null mouse brain. Nat Neurosci 2015;18(11):1559-61. PMID 26352792
210: Yu L, Boyle PA, Nag S, et al. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol Aging 2015;36(11):2946-53. PMID 26341746
211: Zhang WW, Lempessi H, Olsson Y. Amyloid angiopathy of the human brain: immunohistochemical studies using markers for components of extracellular matrix, smooth muscle actin, and endothelial cells. Acta Neuropathol 1998;96:558-63. PMID 9845284
212: Zhang Y, Wang X, Schultz C, Lanzino G, Rabinstein AA. Post-operative outcome of cerebral amyloid angiopathy-related lobar intracerebral hemorrhage: case series and systematic review. Neurosurgery 2012;70(1):125-30. PMID 21937942
213: Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006;16:30-9. PMID 16612980
214: Zhu YC, Dufouil C, Soumare A, Mazoyer B, Chabriat H, Tzourio C. High degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of dementia. J Alzheimers Dis 2010a;22(2):663-72. PMID 20847444
215: Zhu YC, Tzourio C, Soumare A, Mazoyer B, Dufouil C, Chabriat H. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study. Stroke 2010b;41(11):2483-90. PMID 20864661

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Anand Viswanathan MD PhD

Dr. Viswanthan of Harvard Medical School received consulting fees from Alynalam Pharmaceuticals and Biogen.
See Profile
Maria Clara Zanon Zotin MD

Dr. Zanon Zotin of Harvard Medical School has no relevant financial relationships to disclose.
See Profile
Mariel Kozberg MD PhD

Dr. Kozberg of Massachusetts General Hospital received sponsored research from Therini Bio as an investigator and a consulting fee from Kisbee Therapeutics.
See Profile

Editor

Steven R Levine MD

Dr. Levine of the SUNY Health Science Center at Brooklyn has no relevant financial relationships to disclose.
See Profile

Former Authors

Harry S Greenberg MD
Andreas Charidimou MD PhD
Jeffrey L Saver MD, Chelsea S Kidwell MD, and Harry V Vinters MD (original authors)

Patient Profile

Age range of presentation: 45 to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor

autosomal dominant
Population groups selectively affected: Dutch

English

Flemish

Hungarians

Icelanders

Japanese
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Intracerebral hemorrhage: 431

Cerebral infarction: 436

Transient ischemic attack: 435
ICD-10: Intracerebral haemorrhage, unspecified: I61.9

Stroke, not specified as haemorrhage or infarction: I64

Transient cerebral ischaemic attacks and related syndromes: G45
OMIM: Hereditary cerebral hemorrhage with amyloidosis—Icelandic type: #105150

Hereditary cerebral hemorrhage with amyloidosis—Dutch type: #605714

Hereditary cerebral hemorrhage with amyloidosis—Flemish type: #605714

Oculoleptomeningeal amyloidosis: #105210

Familial Alzheimer's disease: #104300, *104760.0002, *104760.0003, *104760.0004, *104760.0008, *104760.0009

Amyloid beta A4 precursor protein: *104760

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Cerebral amyloid angiopathy

Associated Disorders

Alzheimer disease
CAA
Chronic traumatic encephalopathy
Dementia with Lewy bodies
Down syndrome
- Infratentorial superficial siderosis
- Intracerebral hemorrhage
- Ischemic stroke
- Leukoaraiosis
- Lobar hemorrhage
- Malignant neoplasms and radiation necrosis
- Memory loss
- Nontraumatic intracerebral hemorrhage
- Other dementias
- Primary CNS angiitis
- Prion disease
- Seizures
- Superficial siderosis
- Vascular cognitive impairment and dementia
- VCID
- Malignant hypertension
- Hypertensive hemorrhage
- Arteriovenous malformations
- Cavernous hemangiomas
- Hemorrhage into cerebral neoplasms
- Trauma
- Vasculitis
- Coagulopathies
- Mycotic aneurysms
- Cerebral venous thrombosis
- Hypertensive vasculopathy
- Diffuse arteriosclerosis
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
- Fabry disease
- Moyamoya disease
- Fibromuscular dysplasia

Differential Diagnosis

Hypertensive-related hemorrhage
Ischemic stroke with hemorrhagic transformation
Cerebral venous thrombosis–associated hemorrhage
Arteriovenous malformation–related brain hemorrhage
Hemorrhage-prone brain tumor

Also Relevant

Alzheimer disease
CADASIL
Cerebral arteriopathies
Down syndrome
Lobar hemorrhage
- Neurologic disorders of aging
- Nontraumatic intracerebral hemorrhage
- Primary CNS angiitis
- Reversible cerebral vasoconstriction syndromes

Clinical Categories

Patient Handouts

Stroke (hemorrhagic)

Web References

Clinical Trials

NIH: Intracerebral Hemorrhage

Cerebral amyloid angiopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Pathophysiology

Genetics

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Table 1. Boston Criteria Version 2.0 For Diagnosis of Cerebral Amyloid Angiopathy

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Metal neurotoxicity

Vascular cognitive impairment

Ischemic stroke

Cerebral embolism

Hormonal contraception and stroke

Antiphospholipid antibody syndrome

Addictive disorders

Automatic-voluntary dissociation

This is an article preview.
Start a Free Account
to access the full version.